H8H- MC-LAIJ Protocol (b) 
 
 
Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks   
 
 
NCT 03670810 
 
Approval Date 30- Mar-2020 
H8H-MC-LAIJ(b) Clinical Protocol Page 1
LY573144Protocol H8H-MC-LAIJ(b)
Randomized Controlled Trial of Lasmiditan Over Four
Migraine Attacks (CENTURION)
EU Trial Number:  2018 -001661 -17 
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_886826] (LY573144 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries .  
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from pu blic disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise d isseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Lasmiditan (LY573144)
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_229490] 07 May 2018
Amendm ent(a) Electronically Signed and Approved by [CONTACT_229490] 20 Nov 2018
Amendm ent(b) Electronically Signed and Approved by [CONTACT_57968] .
Approval Date: 30-Mar-2020 GMT
H8H-MC-LAIJ(b) Clinical Protocol Page 2
LY573144Table of Contents
Section Page
Protocol  H8H -MC-LAIJ(b) Rando mized Controlled Trial o f Lasmiditan 
Over Four Migraine Attacks (CENTURION) ...................................................................... [ADDRESS_1240863] ivities....................................................................................................... 12
3. Intro duction ...................................................................................................................... 17
3.1. Study  Rati onale ............................................................................................................ 17
3.2. Background .................................................................................................................. 17
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_1240864] ives and Endpo ints.................................................................................................. 20
5. Study  Design ..................................................................................................................... 23
5.1. Overall Design ............................................................................................................. 23
5.1.1. Screening (Visit 1) ............................................................................................... 24
5.1.2. Randomization (Visit 2) ....................................................................................... [ADDRESS_1240865] ions.................................................................................................... 31
6.4. Screen Failures ............................................................................................................. 31
7. Treatments ........................................................................................................................ 32
7.1. Treatments Administered ............................................................................................. 32
7.1.1. Packaging and Labelling ...................................................................................... 33
7.2. Method of Treatment Assignment ................................................................................ 33
7.2.1. Selection and Timing o f Doses:  Study  Treatm ent and Other 
Migraine Treatm ents............................................................................................ 33
7.3. Blinding ....................................................................................................................... 34
7.4. Dosage Modification .................................................................................................... 34
7.5. Preparati on/Handling/Storage/Accountabilit y............................................................... 34
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240866] to Follow -Up........................................................................................................ 39
9. Study  Assessments and Procedures ................................................................................... 40
9.1. Efficacy Assessments ................................................................................................... 40
9.1.1. Primary Efficacy  Assessments ............................................................................. 40
9.1.2. Secondary  Efficacy  Assessments .......................................................................... 40
9.1.3. Appropriateness of Assessments .......................................................................... 42
9.2. Adverse Events ............................................................................................................ 43
9.2.1. Serious Adverse Events ........................................................................................ 43
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 45
9.2.2. Com plaint Handling ............................................................................................. 45
9.3. Treatment of Overdose .................................................................................................45
9.4. Safety........................................................................................................................... 45
9.4.1. Electrocardiograms .............................................................................................. 45
9.4.2. Vital Signs ........................................................................................................... 45
9.4.3. Laboratory  Tests .................................................................................................. 46
9.4.4. Other Tests ........................................................................................................... 46
9.4.5. Safety Moni toring ................................................................................................ 47
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. 47
9.5. Pharmacokinet ics......................................................................................................... 47
9.6. Pharmacodynamics ...................................................................................................... 47
9.7. Genet ics....................................................................................................................... 47
9.7.1. Who le Blood Sample for Pharmacogenet ic Research ........................................... 47
9.8. Biomarkers ................................................................................................................... 48
9.9. Medical Resource Utilizat ion and Healt h Economics ................................................... 48
10. Statistical Considerations .................................................................................................. 49
10.1. Sample Si ze Determinat ion.......................................................................................... 49
10.2. Popul ations for Analyses .............................................................................................. 49
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240867] ical Considerat ions........................................................................ 50
10.3.2. Treatment Group Comparabilit y........................................................................... 51
[IP_ADDRESS]. Patient Disposi tion.......................................................................................... 51
[IP_ADDRESS]. Patient Characteri stics.................................................................................... 51
[IP_ADDRESS]. Concomitant Therapy ..................................................................................... 51
[IP_ADDRESS]. Com pliance .................................................................................................... 52
10.3.3. Efficacy Analyses ................................................................................................ 52
[IP_ADDRESS] .Primary Analyses ........................................................................................... 52
[IP_ADDRESS]. Secondary  Analyses ........................................................................................ 52
[IP_ADDRESS]. Terti ary/Exploratory  Analyses ........................................................................ 53
10.3.4. Safety Analyses .................................................................................................... 53
[IP_ADDRESS]. Treatment -Emergent Adverse Events .............................................................. 53
[IP_ADDRESS]. Columbia -Suicide Severit y Rating Scale ......................................................... 54
[IP_ADDRESS]. Vital Signs
...................................................................................................... 54
[IP_ADDRESS]. Labs ............................................................................................................... 54
[IP_ADDRESS]. Assessme nt of Driving Accidents ................................................................... 54
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 54
10.3.6. Evaluat ion of Immunogenicit y............................................................................. 54
10.3.7. Other Analyses ..................................................................................................... 54
[IP_ADDRESS]. Health Economics ........................................................................................... 54
[IP_ADDRESS]. Subgroup Analyses ......................................................................................... 54
10.3.8. Interim Analyses .................................................................................................. 55
11. References ........................................................................................................................ 56
12. Appendices ....................................................................................................................... 59
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240868] ives and Endpo ints............................................................................... 20
Table LAIJ.5.1. Treatment Group Sequences .......................................................................... 24
Table LAIJ.7.1. Treatment Regimens ...................................................................................... 32
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240869] of Figures
Figure Page
Figure LAIJ.5.1. Illustrati on of  patient fl ow design for Protocol  H8H -MC-LAIJ. ..................... 24
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240870] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 60
Appendix 2. Clinical Laboratory  Tests ............................................................................... 63
Appendix 3. Study  Governance Considerat ions.................................................................. 64
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 68
Appendix 5. Diagnostic Cri teria for Sel ected Mi graine Ty pes............................................ 69
Appendix 6. Medicat ion Overuse Headache Diagnostic Criteria ........................................ 72
Appendix 7. eDiary Assessments ....................................................................................... 73
Appendix 8. Protocol  Amendment H8H -MC-LAIJ(b)Summary ........................................ 74
H8H-MC-LAIJ(b) Clinical Protocol Page 8
LY5731441.Synopsis
Title of Study:
Protocol  H8H -MC-LAIJ Rando mized Controlled Trial of Lasmiditan Over Four Migraine 
Attacks (CENTURION)
Rationale: 
In 2Phase [ADDRESS_1240871] bot hersome symptom 
(MBS) at [ADDRESS_1240872] ives/Endpoints:
Objectives Endpoints
Primary
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on migraine headache pain 
freedom compared to placeboThe proportion of patients in each group that are pain-free
(defined as mild, moderate ,or severe headache pain 
becoming none) at 2hours post dose during the first attack 
To evaluate the consistency of response to 
lasmiditan 200 mg and 100 mg compared to 
placeboThe proportion of patients in each group that are pain-free 
(defined as mild, moderate, or severe headache pain 
becoming none) at [ADDRESS_1240873] 2 out of 
3attacks
Secondary
     Efficacy
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on freedom from MBS compared 
to placeboThe proportion of patients in each group that are free of 
MBS associated with migraine at [ADDRESS_1240874] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on pain relief compared to 
placeboThe proportion of patients with pain relief (defined as 
modera te or severe headache pain becoming mild or none 
and mild pain becoming none) in each group at [ADDRESS_1240875] attack.
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on sustained freedom from pain 
compared to placeboThe proportion of patients in each group with [ADDRESS_1240876] 
attack defined as pain -free at 2 and 24 hours, and 2 and 48 
hours, respectively, with no rescue medication
To evaluate the need for rescue medication in 
patients treated with lasmiditan 200 mg and 
100 mg compared to placeboThe proportion of patients in each group requiring rescue 
medication for migraine within [ADDRESS_1240877] attack
To evaluate the efficacy of lasmiditan 200 mg 
and100 mg at 2 hours on freedom from 
symptoms associated with migraine compared 
to placeboThe proportion of patients in each group that are free of 
symptoms associated with migraine at [ADDRESS_1240878] attack, including each of the followin g:  
phonophobia, photophobia, nausea, and vomiting
H8H-MC-LAIJ(b) Clinical Protocol Page 9
LY573144Objectives Endpoints
Secondary, Efficacy , continued
To assess the probability of migraine relapse 
in patients treated with lasmiditan 200 mg and 
100 mg compared to placeboThe proportion of patients in each group with migraine 
recurrence at [ADDRESS_1240879] attack 
defined as return of any headache in patients who were 
pain-free at 2 hours.
To explore the time course of lasmiditan 200 
mg and 100 mg efficacy compared to placeboThe prop ortion of patients in each group at each time 
point with pain freedom, pain relief, freedom from MBS, 
and no disability postdose during first attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on migraine -related disability 
compared to placeboMean change from baseline in total score and individual 
items as measured by [CONTACT_886840], in each group at 
end of study
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on disability during migraine 
attacks compared to placeboThe prop ortion of patients in each group with no 
disability as measured by [CONTACT_886841], at [ADDRESS_1240880] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on PGIC compared to placeboThe proportion of patients in each gro up very much or 
much better as measured by [CONTACT_886842], at [ADDRESS_1240881] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on HRQoL during an acute 
migraine attack compared to placeboMean HRQoL score for domains of social funct ioning, 
migraine symptoms, and feelings/concerns, as measured 
by [CONTACT_941] 24- hour MQoLQ, in each group at [ADDRESS_1240882] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on treatment satisfaction 
compared to controlThe proportio n of patients in each group who are satisfied 
with their treatment at EoS as measured by a 4 -item 
questionnaire
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on health utility compared to 
placeboMean change from baseline in utility in each gro up as 
measured by [CONTACT_20367] -5D-5L, at [ADDRESS_1240883] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg in triptan nonrespo ndersThe proportions of patients in the subpopulation of triptan 
nonresponders thatachieve primary and secondary 
objectives in each group during the first attack
The proportions of patients in the subpopulation of triptan 
nonresponders versus other patients thatachieve primary 
and secondary objectives in each group during the first 
attack
     Consistency
To evaluate the consistency of lasmiditan 200 
mg and 100 mg on migraine headache pain 
relief in 2 out of 3 attacks compared to 
placeboThe proportion of patients with pain relief (defined as 
moderate or severe headache pain becoming mild or none 
and mild pain becoming none) in each group at [ADDRESS_1240884] 2 out of 3 attacks
To evaluate the consistency of response to 
lasmiditan 200 mg and 100 mg in 3 out of 4 
attacks compared to controlThe proportion of patients in each group that are pain-free 
(defined as mild, moderate, or severe headache pain
becoming none) at [ADDRESS_1240885] 3 out of 
4attacks
To evaluate the consistency of lasmiditan 200 
mg and 100 mg on migraine heada che pain 
relief in 3out of 4attacks compared to controlThe proportion of patients with pain relief (defined as 
moderate or severe headache pain becoming mild or none 
and mild pain becoming non e) in each group at [ADDRESS_1240886] 3out of 4 attacks
H8H-MC-LAIJ(b) Clinical Protocol Page 10
LY573144Objectives Endpoints
Secondary, Consistency, continued
To evaluate the consistency of lasmiditan 200 
mg and 100 mg in triptan nonrespo nders .The proportions of patients in the subpopulation of triptan 
nonrespo nders versus other patients that achieve 
consistency in each group defined as pain fre edom during 
2 out of 3 attacks
Abbreviations:  24- hour MQoL Q= 24-Hour Migraine Quality of Life Questionnaire; EQ -5D-5L = EuroQol 
5-dimension 5 - level scale ; HRQ oL= He alth-Related Qu ality of Life; MBS = most bothersome symptom; 
MIDAS = Migraine Disability Assessment Test ; PGIC = Patient Global Impression of Change.
Summary of Study Design:   
Study  H8H -MC-LAIJ is a prospecti ve, multic enter, randomized, double -blind, modified -parallel, 
placebo -controlled Phase 3 study  of adul tpatients suffering fro m migraine with or wi thout aura.  
Treatment Arms and Duration:   
One treatm ent group will receive lasmiditan [ADDRESS_1240887] of 2 treatment sequence groups 
(1:1) where 1 group will receive lasmiditan for attack 3 and the other group will receive 
lasmiditan f or attack 4.
For rescue (pain freedo m not achi eved) or recurrence (pain freedo m achieved but then pain 
recurs) ,patients may take their own unexcluded medi cationsbeginning at least 2 hours postdose ; 
patients MUST NOT take triptan, ergot, opi[INVESTIGATOR_2480], or barbit urate m edicat ions wi thin 24 hours of 
taking study  drug (that i s, 24 hours before or after) .
To avoi d different ial drop out whi ch coul d com promise the validit y of the study , pati ents shoul d 
not be informed about the treatment groups; instead, patients shou ld be informed that no patient 
will receive placebo for all attacks.
Number of Patients :
Approximately  [ADDRESS_1240888] attack, and approximately 800 
patients wi th data for consistency assessment .  An additional 200 pati ents m ay be randomized if 
there is an insufficient number of patients with complete data for consistency assessment.
Statistical Analysis:
Efficacy analyses will be c onducted on the intent-to-treat ( ITT)population .  This set includes all 
rando mized patients who use at least [ADDRESS_1240889] attack in the 
lasmiditan 100 -mg group with placebo.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240890] 1 dose of study  drug, regardl ess of whether or not they  undergo any 
study  assessments. Patients will be evaluated by  [CONTACT_886843], not by  [CONTACT_886844] .
H8H-MC-LAIJ(b) Clinical Protocol Page 12
LY5731442.Schedule of A ctivities
H8H-MC-LAIJ(b) Clinical Protocol Page 13
LY573144Table LAIJ.2.1. Schedule of Activities
Visit 1a
ScreeningVisit 2
Baseline
(at site)Treatment Attack 1 -4b
All attacks:  Mod /sev within 4 hrs of onset
Atta ck 2:  ≥48 hrs after dosing Attack 1
Attack 3:  ≥48 hrs after dosing Attack 2
Attack 4:  ≥48 hrs after dosing Attack 3Visit6 EoS 
(at site)
or EDCcNotes
V1+3 -30
days
(pending 
lab 
results )Visit 3 
Phone Call 
1 after 
Attack 1 or
at 1 mod±1 
wk after V2Visit 4 
Site Visit
at +2 mos±1 
wk after V2 Visit 5 
Phone Call 2 
at 3 mos±1 
wk after V2≥[ADDRESS_1240891] treated 
attack (=last 
dose) ORat 4
mos±2 wks after 
V2
Obtain informed consent X
Inclusion and exclusion X
Introduce eDiary (V1)
including assess patient 
capability to use eDiaryX
Demographics X
Vital signs X X XTemperature, BP, pulse. 
BP/pulse measured sitting
before blood draws , dosing.  
Use local BP equipment.
Weight X X
Height X
Menstrual cycle status X X X X XFemales asked to provide dates 
and durations of menstrual 
period; table included in paper 
journal to record between visits.
Review migraine history 
including prior treatmentX
Review medical history and 
concomitant medicationX
Physical examination X X
Neurological exam X X
H8H-MC-LAIJ(b) Clinical Protocol Page 14
LY573144Document migraine 
characteristics per IHS criteria X
Complete MIDAS X X
C-SSRS -BL/screening 
versione X
C-SSRS -since last visit 
versione X X X
   Self-Harm Supplement Form X X X X
   Self-Harm Follow -up Form fX X X X
12-lead ECG XPatients must be supi[INVESTIGATOR_2525] 5 to 
10 min before ECG collection 
and remain supi[INVESTIGATOR_886827] .
Clinical laboratory 
(hematolog y, serum chemistry, 
urinaly sis)X X XHepatic algor ithm triggered in 
casesof hepatic ab normalities 
identified by [CONTACT_841742].
Serum pregnancy test or FSH X X XPregnancy tests assessed in 
WOCBP (serum as indicated; 
urine more frequently if 
mandated by [CONTACT_427]); 
FSH assessed as appropriate 
(details in Inclusion Criterion 
#7)
Urine drug screen XCan be repeated once if result is 
positive.
Pharmacogenetic sample 
(genetic sample/DNA)X
Confirm eligibility X
Patient training video X
Randomization X
Dispense study drug X
Provide study eDiary and 
provide detailed instructions
and complete EQ -5D-5LX
H8H-MC-LAIJ(b) Clinical Protocol Page 15
LY573144Migraine attack ( eDiary )
documentation by [CONTACT_886845] (Appendix 7 )
andfrom V2 to EoS ,will be 
reminded daily to record AEs 
and new conmeds in paper 
journal.
mTOQ -6 X
HCRU X X
Employment status X X
Assessment of driving 
accidents/violationsX X X
Treatment Satisfaction X
Verify  any eDiary or study
drug issues, assess compliance 
all procedures, provide 
instructio ns if neededX X X
Determine compliance study 
drugX X
Documentation of 
rescue/recurrence medication X X X X
Documentation of AEs and 
concomitant medicationX X X X X X
Collect unused/empty study 
drug pack and eDiaryX
H8H-MC-LAIJ(b) Clinical Protocol Page 16
LY573144Abbreviations:  24-hour MQoL Q= 24- Hour Migraine Quality of Life Questionnaire; AE = adverse event; BP = blood pressure; conmed = concomitant 
medication; C-SSRS = Columbia Suicide Severity Rating Scale ;DNA = deoxyribonucleic acid; ECG = electrocardiogram; EDC = early discontinuation; eDiary
= electronic diary; EoS = end of study; EQ-5D-5L = EuroQol 5 Dimension 5 Level ; FSH = follicle -stimulating hormone; HCRU = Health Care Resource 
Utilizatio n; hrs = hours; IHS = International Headache Society; MIDAS = Migraine Disability Assessment Test ; min = minutes; mo/mos = month/ months; mod = 
moderate; mTOQ -6= Migraine Treatment Optimization Questionnaire; PGIC = Patient Global Impression of Change; QoL = quality of life; sev = severe; V = 
visit; WO CBP = women of child -bearing potential (see Inclusion Criterion #7 for details) ; wks = weeks .
aV1 activities to be collected outside migraine attack .
bAttacks treated do not need to be consecutive. Minimum amount of time between attacks is 48 hours (determined by [CONTACT_886846] , i.e.,the next attack 
may not be treated with study drug within 48 hours of taking study drug ).  During the treatment period, unscheduled visits may be completed at the discretion 
of the investigator.   In the event of abnormal laboratory fin dings, including but not limited to tests that may indicate abnormal liver function, repeat or 
additional laboratory testing may be required outside a scheduled clinic visit.
cPatients that do not treat a migraine with study drug for any reason during the study should attend an EoS visit to return unused study drug and the eDiary . 
No other assessments are required.
dPhone call after a ttack [ADDRESS_1240892].
eAdapted for the assessment of th e ideation and behavior categories only (the Intensity of Ideation and Lethality of Behavior sections are removed ).
fRequired if triggered by [CONTACT_47584] -Harm Supplement Form per instructions.
H8H-MC-LAIJ(b) Clinical Protocol Page 17
LY5731443.Introduction
3.1. Study Rationale
Pi[INVESTIGATOR_886828] c response over m ultiple attacks . In 2 Phase 3 single 
migraine attack studies, lasmiditan demonstrated statistically significant superi orityversus 
placebo in the proporti on of  patients who were headache pain-free at 2 hours postdose as well as 
the proporti on of  patients who were free of their migraine -associ ated mostbothersome symptom s 
(MBS) at [ADDRESS_1240893] 2 out of 3 att acks.
3.2. Background
Migraine is a commo n neurological disorder and was ranked by [CONTACT_122597] h Organizat ion 
(WHO) in their [ADDRESS_1240894] comm on disease in the wor ld among both males and females (Steiner et al. 
2013).   Migraine prevalence was est imated to be 11.6% (Woldeamanuel and Cowan, 2017). 
Regional crude migraine prevalence was 16.4% in Central  and South America ,11.4% in Europe, 
10.4% in Africa, 10.1% in Asia, and 9.7% in North America.   
Although the introduction of triptans improved the acute treatment of migraine ,somepatients 
still lack adequate treatment. A recent analysis o fthe American Migraine Prevalence and 
Prevent ion study concluded that 40% of patients wit h epi[INVESTIGATOR_39751] c migraine have significant unmet 
needs; the most frequent complaints were headache
-related disa bility (19%) and di ssatisfaction
with current medicat ions (15%) ( Buse et al. 2012).
Treatment of patients wi th migraine and known cardi ovascular ( CV)disease or CV risk factors is 
particularly challenging because the incidence o f myocardial  infarct ion, stroke, claudicat ion, 
diabetes, hypertensio n, and hypercho lesterolemia are all higher in individuals wit h migraine 
compared with the general  popul ation (Bigal et al . 2010 ; Adelborg et al. 2018 ). While tri ptans 
are often used as first -line therapy, not all patients with migraine respond to or tolerate triptans.  
In addit ion, concerns about CVsafet y are believed to limit the prescript ion of tri ptans in som e 
patients wi th migraine in the [LOCATION_002] (Dodick et al. 2004).   Hence, there is a significant 
unmet need for novel migraine therapi[INVESTIGATOR_33082] h a di stinct m echanism of act ion from that of 
triptans .  
Other therapi[INVESTIGATOR_886829] i-inflammatory  drugs, opi [INVESTIGATOR_2438], and barbiturates are not 
specifically targeted to treat migraine and have limitat ions.  Nonsteroidal anti -inflammatory  
drugs have limited effect iveness and so me side effects includ inglabeled warning sconcerning
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240895] limited efficacy and carry well  known risks
including overuse, dependency , and adverse effects . For these reasons, there is substant ial unmet 
medical need f or new m edicati onsfor acute treatment of migraine (Lipton et al . 2013; Tfelt -
Hansen & Diener 2012).
Lasmiditan is a high -affini ty, centrally -penetrant , highly select ive 5 -hydroxy tryptamine (5 -HT 
[serotonin]) 1F receptor agonist without si gnificant pharmacological activit y at [ADDRESS_1240896] of care for acute migraine treatment, which were developed for 
their vasoconstri ctor properti es (Hum phrey  et al . 1990 ;Goadsby 2009; Mit sikostas and Tfelt -
Hansen 2012).  Evidence suggests that l asmidi tan exerts i ts therapeutic effects in the treatment of 
migraine by [CONTACT_886847] (Labast ida-Ramírez et al. 2017) without causing vas oconstri ction in human 
coronary  arteri es(Ramadan et al. 2003).
Two Phase 3multic enter ,double -blind ,placebo -controlled lasmidi tan stud ies,including LAH J
with 100- mg and [ADDRESS_1240897] been co mpleted (Lilly 2018 [IB]). The primary  endpoint in 
each study  was the proporti on of  patients who were headache pain-free at 2 hours postdose 
(defined as mild, moderate, or severe headache pain reduced to none) . Inboth studies, this 
endpo int was si gnificant for all doses of lasmiditan versus placebo . The key  secondary  endpoint 
was the proportion of patients who were free of their migraine -associated MBS at 2 hours 
postdose (defined as the associated symptom p resent and i dentified as MBS prior to dosing and 
then absent at 2 hours). In both studies, this endpoint was significant for all doses o f lasmiditan 
versus placebo.
Study  LAHL (an open-label, 12-month s afety study o f lasmidi tan (100 m g and 200 m g) in the 
acute treatment o f migraine)is a Phase 3, prospective, rando mized study in adults wit h migraine .  
Patients who com pleted ei therStudy LAHJ or Study  LAHK were given the opportunit y to enroll 
in Study  LAHL, which is designed to assess the safet y and tol erabilit y oflong-term intermittent 
use of lasmiditan 100 mg and lasmiditan 200 mg for the acute treatment of migraine. Study  
LAHL was init iated on 13 November 2015 and is currently ong oing.  
Lasmiditan is generally well tolerated .  In the Phase 3 studies, a treatm ent-emergent adverse 
event ( TEAE )was defined as an event that first occurred or worsened in severi ty after baseline 
and wit hin [ADDRESS_1240898] or second dose (if applicable) of study drug.  The most common 
TEAEs reported in Study  LAHJ/301 and Study  LAHK/302 weredizziness ,paresthesia ,
somno lence, fatigue,and nausea . Amajo rity of the TEAEs were mild or moderate in severit y
andself-limit ingin nature .
Trials to assess the consistency o f response are recommended by  [CONTACT_886848] (IHS 20 12) and by [CONTACT_3558] ( EMA 2007). Also, in studies of 
patients wi th migraine, consistency of response is one of the most important attributes of 
migraine medications (Lipton et al . 2005).   
H8H-MC-LAIJ(b) Clinical Protocol Page 19
LY5731443.3. Benefit/Risk Assessment
Lasmidi tan has been shown to be effect ive for the treatm ent of acute migraine wit h or wi thout 
aura in adults.  In Phase [ADDRESS_1240899] ivities 
after taking study  drug as described in the informed consent form (ICF) .  Based on the 
statist ically significant and clinically relevant effects of lasmiditan for treatment of acute 
migraine in adults with ident ified safet y issues only  including generally  mild -to-moderate and 
transi ent tol erabil ity issues, the posit ive benefit to risk profile of lasmiditan supports the conduct 
of this study  to further evaluate and understand the efficacy, consistency , and safet y of 
lasmiditan across 4migraine attacks.   
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of lasmidi tan are to be found in the 
Invest igator’s Brochure (IB) .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240900] ives and endpo ints of the study .
Table LAIJ.
4.1. O bjectives and Endpoints
Objectives Endpoints
Primary
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on migraine headache pain 
freedom compared to placeboThe proportion of patients in each group that are pain-free
(defined as mild, moderate ,or severe headache pain 
becoming none) at 2hours post dose during the first attack 
To evaluate the consistency of response to 
lasmiditan 200 mg and 100 mg compared to 
placeboThe proportion of patients in each group that are pain-free 
(defined as mild, moderate, or severe headache pain 
becoming none) at [ADDRESS_1240901] 2 out of 
3attacks
Secondary
     Efficacy
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on freedom from MBS compared 
to placeboThe proportion of patients in ea ch group that are free of 
MBS associated with migraine at [ADDRESS_1240902] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on pain relief compared to 
placeboThe proportion of patients with pain relief (defined as 
moderate or severe headache pain becoming mild or none 
and mild pain becoming none) in each group at [ADDRESS_1240903] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on sustained freedom from pain 
compared to placeboThe proportion of patients in each group with [ADDRESS_1240904] 
attack defined as pain -free at 2 and 24 hours, and 2 and 48 
hours, respectively, with no rescu e medication
To evaluate the need for rescue medication in 
patients treated with lasmiditan 200 mg and 
100 mg compared to placeboThe proportion of patients in each group requiring rescue 
medication for migraine within [ADDRESS_1240905] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg at 2 hours on freedom from 
symptoms associated with migraine compared 
to placeboThe proportion of patients in each group that are free of 
symptoms associated with migraine at [ADDRESS_1240906] attack, including each of the following:  
phonophobia, photophobia, nausea, and vomiting
To assess the probability of migraine relapse 
in patients treated with lasmiditan 200 mg and 
100 mg compared to placeboThe proportion of patien ts in each group with migraine 
recurrence at [ADDRESS_1240907] attack 
defined as return of any headache in patients who were 
pain-free at 2 hours
To explore the time course of lasmiditan 200 
mg and 100 mg efficacy compared to placeboThe pr oportion of patients in each group at each time 
point with pain freedom, pain relief, freedom from MBS, 
and no disability postdose during first attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on migraine -related disability 
compared to plac eboMean change from baseline in total score and individual 
items as measured by [CONTACT_886840], in each group at 
end of study
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on disability during migraine 
attacks compared to placeboThe proportion of patients in each group with no 
disability as measured by [CONTACT_886841], at [ADDRESS_1240908] attack
H8H-MC-LAIJ(b) Clinical Protocol Page 21
LY573144Objectives Endpoints
Secondary, Efficacy , continued
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on PGIC compared to placeboThe proportion of patients in each group very much or 
much better as measured by [CONTACT_886842], at [ADDRESS_1240909] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on HRQoL during an acute 
migraine attack compared to placeboMean HRQoL score for domains of social functioning, 
migraine symptoms, and feelings/concerns, as measured 
by [CONTACT_941] 24- hour MQoLQ, in each group at [ADDRESS_1240910] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on treatment satisfaction 
compared to controlThe proportion of patients in each group who are satisfied 
with their treatment at EoS as measured by a 4 -item 
questionnaire
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg on health utility compared to 
placeboMean change from baseline in utility in each group as 
measured by [CONTACT_20367] -5D-5L, at [ADDRESS_1240911] attack
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg in triptan nonrespo ndersThe proportions of patients in the s ubpopulation of triptan 
nonresponders thatachieve primary and secondary 
objectives in each group during the first attack 
The proportions of patients in the subpopulation of triptan 
nonresponders versus other patients thatachieve primary 
and secondary ob jectives in each group during the first 
attack
     Consistency
To evaluate the consistency of lasmiditan 200 
mg and 100 mg on migraine headache pain 
relief in 2 out of 3 attacks compared to 
placeboThe proportion of patients with pain relief (defined as
moderate or severe headache pain becoming mild or none 
and mild pain becoming none) in each group at [ADDRESS_1240912] 2 out of 3 attacks
To evaluate the consistency of response to 
lasmiditan 200 mg and 100 mg in 3 out of 4 
attacks compared to controlThe proportion of patients in each group that are pain-free 
(defined as mild, moderate, or severe headache pain
becoming none) at [ADDRESS_1240913] 3 out of 
4attacks
To evaluate the consistency of lasmiditan 200 
mg and 100 mg on migra ine headache pain 
relief in 3out of 4attacks compared to controlThe proportion of patients with pain relief (defined as 
moderate or severe headache pain becoming mild or none 
and mild pain becoming non e) in each group at [ADDRESS_1240914] 3out of 4attacks
To evaluate the consistency of lasmiditan 200 
mg and 100 mg in triptan nonrespo ndersThe proportions of patients in the subpopulation of triptan 
nonresponders versus other patients that achieve 
consistency in each group defined as pain f reedom during 
2 out of 3 attacks 
Exploratory
To evaluate in females the efficacy , as 
measured by [CONTACT_886849], of lasmiditan compared to placebo 
on migraine attacks occurring in proximity to 
mensesDuring a 5-day window starting 2 days before the onset of 
menstruation , the proportion of migraine attacks in 
menstruating females with migraine pain freedom , pain 
relief, and MBS freedom at 2 hours after dosing in each 
group 
To evaluate the efficacy of lasmiditan on total 
migraine freedomProportio n of patients in each group who have total 
migraine freedom , defined as no pain and no migraine -
associated symptoms , at [ADDRESS_1240915] 
attack
H8H-MC-LAIJ(b) Clinical Protocol Page 22
LY573144Objectives Endpoints
Exploratory , continued
To explore the effect of lasmiditan on the 
consistency of 2 -hour freedom from MBS 
during 2 out of 3 attacksThe proportion of patients in each group that are free of 
MBS associate d with migraine at [ADDRESS_1240916] dose during 
2 out of 3 attacks
To evaluate the efficacy of lasmidit an on 
HRQoL with respect to domains of work 
functioning and energy/vitality during an acute 
migraine attackMean HRQoL score for domains of work functioning and 
energy /vitality , as measured by  [CONTACT_941] [ADDRESS_1240917] attack
To evaluate the efficacy of lasmiditan on 
HCRUMean change from baseline in HCRU in each group
To evaluate the efficacy of lasmiditan 50 mg The proportions of patients with pain freedom, pain relief, 
MBS freedom, no disability, and very much or much 
better as measured by [CONTACT_886842] , at 2 hours postdose in 
patients treated with lasmiditan 50 mg during attacks 3 
and 4 versus placebo during attacks 3 a nd 4
To explore the efficacy of lasmiditan on time 
to meaningful relief and the time to pain 
freedomThe time to meaningful relief and time to pain free dom in 
each group during each attack
Abbreviations:  24- hour MQoL Q= 24-Hour Migraine Quality of Life Questionnaire; EQ -5D-5L = EuroQol 
5-dimension 5 - level scale ; HCRU = Health Care Resource Utilization; HRQ oL= He alth-Related Qu ality of Life; 
MBS = most bothersome symptom; MIDAS = Migraine Disability Assessment Test ; PGIC = Patient Global 
Impression of Ch ange.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240918] ( MIDAS )score ≥11.
The treatm ent group sequences are summari zed in Table LAIJ. 5.1and will include 1treatment 
group that receives lasmiditan [ADDRESS_1240919] of 2treatment sequence groups (1:1) where 1
group will receive lasmiditan for attack 3and the other group will receive lasmiditan for attack 4
.  
Patients will be asked to tre at 4migraine attack swith study  drug on an outpatient basis. Patients 
will be provided with doses for treatm entof all 4 attacks . Each patient’s study  parti cipat ion will 
consist of a screening visit (Visit 1) followed by  a randomizat ion visit (Visi t 2)3-to-30 days after 
screening , a Treatm ent Peri od of  up to 16weeks including phone visit s and 1site visi t, and an 
end-of-study  visit (EoS)at least 7days aftertreating the lastmigraine attack (or at 4 months ±2
weeks after Visi t 2). 
Figure LAIJ. 5.1illustrates the patient fl ow design .
H8H-MC-LAIJ(b) Clinical Protocol Page 24
LY573144Abbreviations:  EDC = ear ly discontinuation; EoS = end of study; hrs = hours; min = 
minimum.
aPreventive treatment allowed (if stable 3 mo nths prior to V1).
bAt each attack patient will tak e 3 tablets to maintain blinding .
cAttacks treated do not need to be consecutive .
dPhone call/Visits will only occur if all 4 attacks are not completed by [CONTACT_14713] .
ePatient will wait to take study drug until migraine pain is moderate/severe ; must 
be the FIRST treatment for the migraine taken within 4 h ours of onset .
Figure LAIJ. 5.1. Illustration of patient flow design for Protocol H8H-MC-LAIJ.
Table LA IJ.5.1. Treatment Group Sequences
Treatment Group 
Sequence sAttack 1 Attack 2 Attack 3 Attack 4
Lasmiditan 200 mg LTN200 L TN200 L TN200 L TN200
Lasmiditan 100 mg LTN 100 LTN 100 LTN 100 LTN 100
Control 1 placebo placebo LTN 50 placebo
Control 2 placebo placebo placebo LTN 50
Abbreviations:  LTN 200= lasmiditan 200 mg; LTN 100 = lasmiditan 100 mg; LTN 50=lasmiditan 50 mg .
To avoi d different ial drop out whi ch coul d bias and com promise the study , pati ents shoul d not be 
inform ed about the treatm ent group sequences described in Table LAIJ. 5.1.  Instead, patients 
shoul d be informed that no patient will receive placebo for all attacks.
5.1.1. Screening (Visit 1)
At the screening visit (Visit 1) patients will provide written informed consent and will be 
screened to review the inclusio nand exclusio n criteria.  Study  eligibilit y will be assessed on the 
basis of medical history  including detailed migraine history meet ing the International 
Classificat ion of Headache Disorders ( ICHD )
-3classificat ion 1.1 or 1.2 .1for migraine , onset of 
migr aine pri or to age 50, 3 to 8 migraine attacks per month but <[ADDRESS_1240920] 3 months , baseline physical examination, vital signs, clinical laboratory  tests, 12 -
lead electrocardi ogram  (ECG )and responses to the MIDAS quest ionnaire indicat ing disabling 

H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240921] 6 months and/or related resource utilizatio n such as visits to cardio logists, procedu res, 
hospi [INVESTIGATOR_36651], new treatm ents or treatm ent adj ustm ents for CV disease. A Columbia -Suicide 
Severit y Rating Scale ( C-SSRS )will be com pleted. Patient s will receive so me initial 
introducti on to the electroni c diary ( eDiary )and the site will assess whether the pati ent is willing 
and able to use the eDiaryto record data during their migraine attacks . 
See Table LAIJ .2.1for a com plete list o f assessments performed at Visit 1.
For pati ents not m eeting study  requi rements at the screening visit or found to not qualify based 
on laboratory  assessments, there will be no addit ional site visi ts. 
5.1.2. Randomization (Visit2)
At Visit 2, p atients will be rando mly assigned treatment as described in Section 5.1, will have 
additional assessments (see Table LAIJ .2.1), will be dispensed study  drug , and will begin the 
Treatment Period .  If available and where local regulat ions and ethical review boards (ERBs) 
allow, patients will also watch a training video designed to address patient expectations with 
regard to participat ion in a placebo -controlled trial and the difference between medica l treatm ent 
and research. The patientwill receive detailed instruction on the use of the eDiaryand on dosing 
theirmigraine attacks with study  drug.  
5.1.3. Treatment Period
During the treatment period, patients will part icipate i n phone visits after attack 1 orat 1 month
(whichever comes first) and at [ADDRESS_1240922] dose time points:  0.5, 1, 2, 4, 6, 24,and [ADDRESS_1240923] a 48 -hour 
gap after taking study  drug for the treated attack ,before treating the next migraine wit h study  
drug.  
For migraine attacks which do not meet the criteria above or when the pati ent is unable to treat 
with study  drug and com plete all  study  procedures during a particular migraine, they  may use 
their usual  migraine m edicati on for that migraine and then treat the next appropriate migraine 
with study  drug.  In summary , patient s are requested to treat 4consecut ive appropriate migraine
attack s with study  drug, but this is not required if it is not possible .  
As described in detail in Section 7.2.1 ,patients requiring medicat ion for rescue or for migraine 
recurrence may take thei r own unexcluded medicatio n. 
Study  governance considerations are described in detail in Appendix 3 .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240924] patient . 
5.4. Scientific Rationale for Study Design
The patient populat ion for this study  will cl osely align to the study  popul ation stu died in the 
lasmiditan Phase 3 program to date.
A modified parallel design was chosen after consideration of mult iple design options.  The 
modified parallel design was previously  used successfully  to assess the consistency  of 
telcagepant over 4 attacks (Ho et al . 2010) .  This design was chosen over a parallel 
placebo -controlled design because o f reduced risk of unblinding leading to differential drop -out 
rates .  
A frequent ly used approach , term edrando m-insertio n-of-placebo, is for each patient toreceive 
placebo for 1 of their attacks.   However, relat ive to this approach, the modified parallel approach 
in this study  has beneficial features, including the opportunit y to study  the consistency  of 
response to 2 doses of lasmiditan (100 mg and 200 mg) with a relatively simple study design.  
Finally , while random -insert ion-of-placebo provi des the consistency  of treatm ent, i t does not
provi de an opportunit yfor comparing the consistency of effect in pa tients treated with drug 
versus placebo .
The efficacy of lasmiditan [ADDRESS_1240925] attack by  
[CONTACT_886850] h placebo in th e control  group .
The number of attacks is 4and the durati on of  the treatm ent phase of the study  is up to 16weeks. 
Patients wi th 3to8 migraine attacks per month will be recruited to increase the probabilit y that 
patients will  achieve 1or more evaluable migraine attacks per month as recommended in the IHS 
guideline ( IHS Clinical Trials Subco mmittee 2012 )
.
Inclusion of the control group
The inclusio n of the control group provides the opportunit y to com pare the efficacy and 
consistency of response to lasmiditan [ADDRESS_1240926] in acute trea tment of 
migraine varies from 6% to 47%, highlighting the importance of co mpar ing act ive study  drug to 
placebo . Because rescue medication is permitted after 2 hours, the use of placebo in the design 
is ethically  appropri ate(Lipton et al . 2005) . 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240927] been co mpleted, and these studies show 
dose-dependent efficacy of lasmiditan versus placebo to increase freedo m from both pain and 
MBS with lasmidi tan.  All doses (50 m g, 100 m g, and 200 m g)showed stati stically significant 
superi ority versus pl acebo on pain freedom, MBS freedo m, and pain relief versus placebo.  In 
general, the eff icacy  of lasmidi tan was dose dependent ,with lasmiditan [ADDRESS_1240928] acebo , incl uding dizziness, paresthesia, so mnolence, 
fatigue, nausea, and lethargy.  In general, these TEAEs were observed to increase in a dose -
dependent manner (ie, they  were l owest wi th lasmidi tan [ADDRESS_1240929] wi th lasmidi tan 
200mg).  These TEAEs were usually mild tomoderate i n severi ty andself-limit ing.  Because of 
the relatively greater efficacy of lasmiditan 100mg and 200 mg, the main study arms will be 
lasmiditan 100 mg, lasmiditan 200 mg, and control.  To further understand the effects of
lasmiditan 50 mg, the control group will receive lasmiditan 50 mg for 1attack.
H8H-MC-LAIJ(b) Clinical Protocol Page 28
LY5731446.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also kno wn as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet all  of the f ollowing criteria at 
screening :
Type of Patient and Disease Characteristics
[1] are of an acceptabl e age to provi de inform ed consent accordi ng to the l ocal regul ations 
and are at least 18years of age at time of screening ( Visit1) wi th migraine with or 
without aura fulfilling the IHS diagnostic criteria 1.1 or1.2.1(ICHD -
3;see Appendix 5 )
[2] history  of disabling migraine for at least 1 year
[
3] migraine onset before the age of 50 years
[4] history  of 3to8 migraine attacks per month (<15 headache days per month) during the 
past 3 m onths
[5] MIDAS score ≥11
[
6] able and willing to complete an eDiary to record the details of each migraine attack 
treated with study  drug
Patient Characteristics
[7] are men or wom en; if wom en, m ustagree to abide by  [CONTACT_941] f ollowing guidance:
women of child- bearing potential must agree to use ahighly effect ive method of 
contraception ( that is, one wi th less than 1% failure rate) such as combinat ion oral  
contraceptives ,implanted/injected contraceptives ,intrauterine devices ,or sterile partner
until [ADDRESS_1240930] dose of study medicat ion
women of child- bearing potential w ho are abstinent (if this is complete abstinence, as 
their preferred an d usual lifestyle) or in a s ame-sex relationship (as part of their 
preferred and usual lifestyle) must agree to either remain abst inent or stay in a same -sex 
relationship without sexual relat ionships wit h males. Periodic abstinence ( for example , 
calendar, ovul ation, symptothermal, pos t -ovulation methods), declarat ion of abst inence 
just for the duration of a trial, and withdrawal are notacceptable methods of 
contraception 
women not of child -bearing potential may participate and include those who are:  
infertile due to surgical ster ilizat ion (hysterectomy, bilateral oophorectomy , or 
tubal  ligation), congenital ano maly such as m ullerian agenesis; or  
post-menopausal –defined as either  
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240931] uterus, not on 
horm one therapy , who has had 
cessation of menses for at least 1 y ear, and   
a follicle -stimulat ing hormone >40 mIU/mL;
oa wom an at l east [ADDRESS_1240932] uterus, not on hormone 
therapy , who has had either  
cessat ion of menses for at least 1 y ear, or  
at least 6 m onths of spontaneous amenorrhea with a fo llicle -
stimulat ing hormone >40 mIU/mL; or 
oa wom an [ADDRESS_1240933] 6 
months of spontaneous amenorrhea; or  
oa wom an at l east [ADDRESS_1240934] acement therapy    
Informed Consent
[8] are able and willing to give signed informed consent
[9] agree not to post any  personal medical data related to the study  orinformation related to 
the study  on any website or social media site ( eg,Facebook, Twitter, LinkedIn, Google+, 
etc.) until the ent ire trial  hascompleted
6.2. Exclusion Criteria
Patients will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening:
Medical Conditions /Prior a nd Concomitant Therapy
[10] known hypersensit ivity to lasmidi tan, or to any  exci pi[INVESTIGATOR_886830] 
[11] history  or evi dence of hemorrhagic stroke, epi[INVESTIGATOR_002] ,or any  other condi tion pl acing the 
patientat increased risk of seizures
[
12] history  of recurrent di zziness and/or verti go incl uding benign paroxysmal posi tional 
vertigo,Meniere’s disease, vest ibular migraine, and other vest ibular disorders   
[13] history  of diabetes m ellituswith com plicat ions (diabet ic retinopathy, nephropathy, o r 
neuropathy )
[14] history  of orthostatic hypotension wit h syncope
[15] significant renal or hepatic impairment in the opi[INVESTIGATOR_886831] (see Section [IP_ADDRESS] )
[
16] pati ents who, in the investigator’s judgment, are actively  suicidal  andtherefore deemed to 
be at si gnificant risk for suicide, or those who have answered “yes” to either Question 4 
(Active Suicidal Ideat ion with Som eIntent to Act, Wit hout Specific Plan) or Question 5 
H8H-MC-LAIJ(b) Clinical Protocol Page 30
LY573144(Active Suicidal Ideat ionwith Specific Plan and Intent) on the “Suicidal Ideat ion” 
porti on of  theC–SSRS, or answer “yes” to any  ofthe suicide -related behaviors (actu al 
attem pt, interrupted attempt, aborted attempt, preparatory  act or behavior) on the 
“Suicidal Behavior” portion of the C
–SSRS; and the ideat ion or behavior occurred within 
the past m onth of Vi sit
1or2
[17]Exclusio n criterion [17] has been deleted.
[
18] history , within past 12 m onths, of chronic migraine or other forms of primary  or 
secondary  chronic headache disorder (eg ,hemicranias continu a, medicati on overuse 
headache where headache frequency is ≥15 headache days per month [Appendix 5 and 
Appendix 6 ]
)
[19] use of more than 3 doses per month of eit her opi [INVESTIGATOR_886832]
[
20] i nitiation of or a change in conco mitant m edicat ion to reduce the frequency of migraine
epi[INVESTIGATOR_212908] 3months pri or to Screening/Visit 1
[21] female patients who are pregnant or breast -feeding
[22] women of child -bearing potenti al who test posit ive for pregnancy based on a serum 
pregnancy test collected at Visit 1
[23] history  of drug or al coho l abuse/dependence within 1 y ear pri or to Vi sit 1 
(excessive or compulsive use as judged by [CONTACT_093]), or currently using 
drugs of potenti al abuse or any  prescribed or over -the
-counter medicat ion in a 
manner that the invest igator considers indicat ive of abuse/dependence
[24] h ave a posi tive urine drug screen for any substances of abus e at Vi sit 1
Note :  A retest is allowed if the urine drug screen is posit ive for any prescribed 
substance or if, in the judgment of the invest igator, there is a medically acceptable 
explanat ion for the posit ive result .  
The results of the retest m ust be negat ive at or 
prior to Visit 2
[25] h ave an acute, serious or unstable medical condit ion, or a hi story  or presence of 
any other medical illness including but not limited to any autoimmune disease, 
CV, hepat ic, respi[INVESTIGATOR_696], hematological, en docrine, psy chiatri c
,or neurol ogical 
disease, or any  clinically significant laboratory  abnorm ality, that ,in the judgment 
of the invest igator, indicates a medical problem  that wou ld preclude study 
participat ion
[26] known hypersensit ivity to multiple drug s
Prior/Concurrent Clinical Trial Experience
[27]are currently enrolled in any other clinical study  involving an invest igational product or 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
[
28] i f patient recent ly took an investigational product , 5 half -lives or 30 day sor requirements 
based on local regul ations
(whichever is longer) should have passed
H8H-MC-LAIJ(b) Clinical Protocol Page 31
LY573144[29] have previously completed or withdrawn fro m this study  or any  other study  
investigat inglasmiditan
Other Exclusions
[
30] are invest igator site personnel direct ly affiliated with this study and/or their 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted
[
31] are Lill y empl oyees 
Patients with test resul ts which did not m eet the incl usion/exclusi on criteria may have the 
relevant test repeated once if it was thought to represent a laboratory  error; a reversible, clinically 
insignificant intermittent condit ion; or was no
t consistent with the patient’s histori cal values.  If 
inclusio n/excl usion criteria were not m et after the repeat test, the patientshoul d not be enrolled 
in the study .
6.2.1. Rationale for Exclusion of Certain Study Candidates
Exclusio n Criteria [ADDRESS_1240935] in study  patients.
6.3. Lifestyle Restrictions
Not applicable.
6.4. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m aybe
considered for rescreen ingonce with approval  from Lilly  Medical  for only the cri teria shown 
below.  The interval between screening and rescreening must be at least 45 days or longer if 
requi red for the specified timeframes in the inclusion/exclusion criteria or concomitant 
medicat ion list.  If rescreening is performed, the individual must sign a new ICF and will be 
assigned a new ident ificat ion number.
Inclusio n Criterion 
[1]:  If patients are less than age 18 at time of informed consent, they  
may be rescreened if they  reach age 18 during the study  enrollment peri od
Exclusio n Criterion[
22]:  false posit ive pregnancy test
Patients using a concomitant medicat ion that requires a stable dose for a specific durat ion prior 
to Visit 2 may  be rescreened if addit ional time is needed to meet the duration requirement . 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240936] of 3tablets for the treatment of a single migraine attack.
lasmidi tan 50 -mg dose –
1 lasmiditan 50-mg tablet and 2lasmiditan 100 mg 
matching placebo
lasmidi tan 100 -mg dose –
1 lasmiditan 100-mg tablet , 1 lasmiditan 50 mg 
matching placebo, and1lasmiditan 100mg matching placebo
lasmidi tan 200 -mg dose – 2 lasmiditan 100-mg tablets and 1lasmiditan 50 mg 
matching placebo
placebo –
1 lasmiditan 50 m g matching placebo and 2 lasmiditan 100 m g 
matching placebo
Table LAIJ.7.1. Treatment Regimens
Regimen Attack 1 Attack 2 Attack 3 Attack 4
LTN 200 mg 
Dose GroupLTN 200mg
2100-mg lasmiditan 
tablets 
150 mg lasmiditan
matching placeboLTN 200 mg
2100-mglasmiditan
tablets
150 mg lasmiditan
matching placeboLTN 200 mg 
2100-mg lasmiditan 
tablets 
150 mg lasmiditan
matching placeboLTN 200 mg 
2100-mg lasmiditan 
tablets 
150 mg lasmiditan
matching placebo
LTN 100 mg 
Dose GroupLTN 100mg
1100-mg lasmiditan 
tablet
150 mg lasmiditan
matching placebo
1100 mg lasmiditan 
matching placeboLTN 100 mg
1100-mg lasmiditan 
tablet  
150 mg lasmiditan 
matching placebo 
1100 mg lasmiditan 
matching placeboLTN 100 mg
1100-mg lasmiditan 
tablet
150 mg lasmiditan 
matching placebo
1100 mg lasmiditan 
matching placeboLTN 100 mg
1100-mg lasmiditan 
tablet
150 mg lasmiditan
matching placebo
1100 mg lasmiditan 
matching placebo
Control 1Placebo
150 mg lasmiditan 
matching placebo
2100 mg lasmiditan
matching placeboPlacebo
150 mg lasmiditan 
matching placebo
2100 mg lasmiditan
matching placeboLTN 50 mg
150-mg lasmiditan 
tablet
2100 mg lasmiditan 
matching placebo Placebo
150 mg lasmiditan 
matching placebo 
2100 mg lasmiditan
matching placebo
Control 2Placebo
150 mg lasmiditan 
matching placebo
2100 mg lasmiditan
matching placeboPlacebo
150 mg lasmiditan 
matching placebo 
2[ADDRESS_1240937] boPlacebo
150 mg lasmiditan 
matching placebo 
2100 mg lasmiditan
matching placeboLTN 50 mg
150-mg lasmiditan 
tablet 
2100 mg lasmiditan
matching placebo
Abbrevi ations:  LTN 200= lasmiditan 200 mg; LTN 100 = lasmiditan 100 mg; LTN 50=lasmiditan 50 mg.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240938] igator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agent to the pati ent 
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Lilly , or i ts desi gnee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by [CONTACT_779], as allowed by [CONTACT_1769]
7.1.1. Packaging and Labelling
Clinical study materials will be labeled according to the country ’s regul atory  requi rements.
7.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to double -blind treatment at 
Visit 2.  Assignment to treatment groups will be determined by a computer -generated random 
sequence using an interactive web
-response system (IWRS) .  Patients will be rando mized 1:1:[ADDRESS_1240939] into the IWRS.
To achieve between -group com parabilit y, the randomizat ion will be stratified by  [CONTACT_1606] .
7.2.1. Selection and Timing of Doses :  Study Treatment and Other 
Migraine Treatments
Patients will  be randomized 1:1:[ADDRESS_1240940] treatment for a new migraine attack.
Themigraine is at least of moderate or severe severi ty.
Migraine shoul dbe treated within 4hours of onset .
No pri or analgesic or acute migraine treatment or symptom -modifying m edicat ion 
(for example, ant iemetic) has been taken to treat th e current migraine attack.
Patients shoul d not take study  drug wi thin 24 hours after taking triptans, ergots, 
opi[INVESTIGATOR_2438], and barbiturates.
Rescue or Recurrence Medication.  Between 2 and 24 hours after dosing, patients may take their 
own unexcluded medicat ion for rescue treatm ent (headache pain freedom is not achieved at 2 
H8H-MC-LAIJ(b) Clinical Protocol Page 34
LY573144hours) or for treatment of recurrent headache (headache pain freedo m is achieved at 2 hours but 
recurs a fter 2 hours) .  Patients should not take anymedicat ions unt il [ADDRESS_1240941] NOT be taken wit hin 24 hours ofstudy  drug 
administration (that is, 24 hours before or after) .  The use of rescue or recurrence medicat ion 
shoul d be recorded in the patient’s paper journal.    
7.3. Blinding
This is a double -blind study .
To preserve the blinding of the study , a minimum number of Lilly  personnel  will see the 
rando mizat ion table and treatment a ssignments before the study  is complete.
Emergency  unblinding for AEs willbe perform ed through the IWR S.  Thi s opti on may  be used 
ONLY if the patient’swell-being requires knowledge of thepatient ’s treatment assignment.  All 
unblinding event sare recorded and reported by  [CONTACT_8784] .
If an invest igator, site personnel performing assessments, or patient is unblinded, the patient
must be discont inued fro m the study .  In cases where there are ethical reasons to have the patient
remain in the study , the investigator m ust obtain specific approval fro m a Lilly clinical research 
physician (CRP) for the patientto continue in the study .
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a pati ent’s treatm ent assignment is warranted for medical management of the event.  The 
patient’s safet y must always be the first consideration in maki ng such a determinat ion.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately.   If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
prom ptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
Upon com pletion of the study , all codes m ust be returned to Lilly  or its designee.
7.4. Dosage Modification
Dosage modificat ion is not allowed.
7.5. Preparation/Handling/Storage/Accountability
The invest igator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transi t for all study  treatm ent received and any discrepancies are reported and 
resolved before use of the study  treatm ent
H8H-MC-LAIJ(b) Clinical Protocol Page 35
LY573144ensuring that only participants enro lled in the study may receive study treatment 
and only  authori zed si te staff may  supply  study  treatment. All study treatments 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h provi ded instructions, with access limi ted to 
the invest igator and authorized site staff
the invest igator, i nstitution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatm ent accountabilit y, reconciliat ion, and 
record m aintenance (such as receipt, reconciliat ion and final disposit ion records)
7.6. Treatment Compliance
Patientcompliance wi th study  drug will be assessed.   Com pliance will be assessed by [CONTACT_657641], counting returned tablets, and so on.   Deviat ion(s) fro m the prescribed dosage 
regimen should be recorded in the case report form ( CRF).
Study  drug will be ta ken by [CONTACT_886851]. Upon review o f eligibilit y at Visit 
2,study drug to treat all [ADDRESS_1240942] 
intentionally  or repeatedly  taken m ore than the prescribed amount of medicat ion.
7.7. Concomitant Therapy
Concomitant medicat ions (including devices )for migraine or pain prior to study
 enrollment and 
concomitant medicat ion used to treat other medical condit ions pri or to study  enro llment will be 
recorded dur ing Screening/Visit 1.
Any changes in dosage or new medicat ions added as a result of intercurrent illness during the 
patient’s time on study  must be recorded in the CRFs.
Use of the following medicat ions is prohibited for the duration of a patient ’s participat ion in the 
study  from Screening/Visit 1 through EoS: 
any invest igational treatment other than lasmiditan 
if a pat ient requi res the init iation of migraine prophylaxis (conco mitant 
medicat ion to reduce the frequency of migraine epi[INVESTIGATOR_1841]) or a change in 
ongoing migraine prophylaxis after the Screening/Visit [ADDRESS_1240943] ive therapi[INVESTIGATOR_886833].
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240944] ivities after taking study  drug as described in the ICF.
Because of the potential o f lasmidi tan to cause central  nervous system  (CNS) -related side effects
(see Section 3.2and IB) , advi se pat ients to use c aution if taking study  medicat ionin co mbination 
with alcohol  or other CNS depressants .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240945] :
Subject Decision
othe patient requests to discont inue invest igational product.
Discontinuation due to a hepatic event or liver test abnormality .  Patients who are 
discontinued fro m invest igational product due to a hepat ic event or liver test abnormalit y 
shoul d have addi tional hepatic safet y data collected via eCRF.
Discontinuati on of  the invest igational product for abnormal liver tests should be
considered by [CONTACT_82378] a patient meets 1 of the f ollowing condi tions after 
consultation wit h the Lilly designated medical monitor:
alanine aminotransferase (ALT) or aspartate amino transferase (AST) >8X 
upper limit of normal (ULN)
ALT or AST >5X U LN for more than 2 weeks
ALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
internat ional norm alized rati o (INR)>1.5
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
alkaline phosphatase (ALP) >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Patients di scont inuing fro m the invest igational product prematurely for any reason should 
complete AEand other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2
(Adverse Events) ,and Section 9.4(Safet y) of this protocol .
8.1.2. Temporary Discontinuation from Study Treatment 
Not applicable for this as needed medication.
8.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ientwho did not meet enrollment criteria and was 
inadvertent ly enro lled, then the patient should be discontinued fro m study  treatm entandsafety 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240946] ion 2(Schedule of Act ivities), Secti on 9.2
(Adverse Events), and Section 9.4(Safet y) of the main protocol .
8.2. Discontinuation from the Study
Patients will  be discont inued in the fo llowing ci rcumstances:
enrollment in any other clinical study  involving an invest igational product or 
enrollment in any other type o f medical research judged not to be 
scientifically or medically co mpatible wit h this study
participat ion in the study needs to be stopped for medical, safet y, regul atory , 
or other reasons consiste nt with applicable laws, regulat ions, and good clinical 
practi ce (GCP)
investi gator decisio n
othe invest igator decides that the patient should be discontinue dfrom the 
study
patientdecision
othe pati
ent requests to discont inue study  drug or to be wit hdrawn from the 
study
patient becom espregnant or is breastfeeding
if a pat ient requi res the init iation of migraine prophylaxis (conco mitant m edicat ion to 
reduce the frequency of migraine epi[INVESTIGATOR_1841]) or a change in ongo ing migraine 
prophylaxis after the Screening/Visit [ADDRESS_1240947] in deciding whether the patient should 
be discont inued fro m study  drug if, during the study , a pati ent 
is, in the invest igator’s judgment, actively suicidal and therefore deemed to be 
at significant ri sk for sui cide
answers “yes” to either Question 4 (Act ive Suicidal Ideat ion with Som e Intent 
to Act, Wi thout Specific Plan) or Question 5 (Act ive Suicidal Ideat ion with 
Specific Plan and Intent) on the “Suicidal Ideation” portion of the C –SSRS, or 
answers “yes” to any  of the sui cide-related behaviors (actual attempt, 
interrupted attem pt, aborted attempt, pr eparatory act or behavior) on the 
“Suicidal Behavior” portion of the C –SSRS; and the ideat ion or behavior 
occurred within the past month of the assessment
When a pat ient discontinues from a study  due to suicidal ideat ion and/or behavior, the 
same fo llow
-upprocedures will be used as would be done for discontinuation due to any 
other AEs l eading to di scont inuat ion.
Patients di scont inuing fro m the study  prem aturely for any  reason shoul d com plete AEand other 
safet y follow-up per Secti on 2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Secti on9.4(Safet y) of this protocol .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240948] vital status informat ion.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240949] ivities (Table LAIJ .2.1), with the study  procedures and their 
timing (including tolerance limit s for timing).
Appendix [ADDRESS_1240950] the date and time of taking study  drug.  Patients will be asked to assess their 
headache severit y at specified time points :  0 (pre dose), 0.5, 1,[ADDRESS_1240951] dose 
using the IHS 4- point headache severit y rating scale (0 = no pain, 1 = mild pain, 2 =moderate 
pain, and 3 = severe pain) (see Appendix 7 ).  
9.1.2. Secondary Efficacy Assessments
Patient Diary
Secondary  efficacy data will also be co llected in theeDiary. 
At the time points 0 (pre dose), 0.5, 1, 
2, 4, 6, 24,and 48 hours, patients willassess the presence 
or absence (yes or no) of accompanying symptoms: photophobia, phonophobia ,nausea ,and 
vomiting. At time 0 (pre dose) patients will select fro m the acco mpanying symptoms present 
(from nausea, phonophobia ,or photophobia only) which one is the m ost bothersom e to them (see 
Appendix 7 ). 
Patients will  also be asked to record the time at which headache relief became meaningful to 
them and the time at whi ch they  become headache p
ain-free. At [ADDRESS_1240952] their global impressio n of change (PGIC ) using a 7 -
point scale (very  much better, m uch better, a litt le better, no change, a litt le worse, much worse, 
and very  much worse) (see Appendix 7 ).
Patients shoul d record d etails of AEs,concomitant medicat ion use , and any  other rel evant 
inform ationin the patient’s paper journal and these will be reviewed at the next visit.
H8H-MC-LAIJ(b) Clinical Protocol Page 41
LY573144Recording Use of Rescue /Recurrence Medication
Between 2 and 24 hours after dosing , pati ents m ay take thei r own unexcluded medicat ion for 
rescue treatment (headache pain freedo m is not achieved at 2 hours) orfor treatm ent of recurrent 
headache.  The use of rescue or recurrence medicatio n shoul d be recorded in the patient ’s paper 
journal .
Migraine Quality of Life Questionnaire (MQoLQ) :  The 24-h ourMigraine Qualit y of Life 
Quest ionnaire (24 -hrMQoLQ) has been specifically developed to measure the HRQoL of 
patients wi th migraine within a 24 -hourperiod after having taken migraine medicat ion.  The 
24-hour MQoLQ is a 15 -item, self - administered questionnaire .  The i tems cover 5 domains 
(work functioning , soci alfunct ioning, energy  and vitality, feelings and concerns, and migraine 
symptoms) (Hartmaier et al .1995; Santanello et al . 1995, 1997) . Each domain consists of 3 
questions answered on a 7
-point scale where 1 indicates maximum impairment and 7 indicat ing 
no impairment .  A domain score is calculated by [CONTACT_886852] 3questions and 
the dom ain score ranges from 3 to 21.  The questionnaire will be administered 24 hours after
dosing wit hstudy drug during each migraine .
MIDAS :  The MIDAS is a pat ient-rated scale which was des igned to quantify headache- related 
disabili ty over a [ADDRESS_1240953] 3 months of assessment, ranging 
from 0 to 90, wi th the total score being the summatio n of the 5 numeric responses.  A higher 
value is indicat ive of more disabilit y (Stewart et al . 1999 , 2001).  This instrument is considered 
reliable and valid, and is correlated with clinical judgment regarding the need for medical care 
(Stewart et al. 1999
,2001).  For clinical interpretabilit y, 4 categori cal grades were developed 
based on the total score :  Grade I (0 to 5) is for litt le or no disabilit y, Grade II (6 to 10) is for 
mild di sabili ty, Grade III (11 to 20) i s for moderate di sabili ty, and Grade IV (21+) is for severe 
disabili ty.  The severe disabilit y category  has subsequent ly been subdivided into Grade IV -A 
(severe [21 to 40]) and Grade IV -B (very severe [41 to 270]) because a high proportion of 
patients wi th chroni c migraine are in Grade IV (Blumenfeld et al. 2011) .  Two addit ional 
questions (A and B) collect informat ion on the frequency o f headac hes and the intensit y of the 
headache pain .  These are not scored in the MIDAS Questionnaire but are included to provide 
clinically relevant informat ion that m ay aid in treatment and management decisio ns.  The 
MIDAS will be captured at screening as part of the inclusio n criteriaand again at EoS with the 
recall period adjusted to capture disabilit y since the patient enrolled in the study  (depending on 
how quickly  the pat ient completes the 4migraine attacks, this could be fro m approximately 1 to 
4 months ). 
mTOQ -6:  The mTOQ is a validated, self -administered questionnaire that assesses the efficacy  
of current acute migraine treatment (Lipton et al . 2009) and is d emonstrated to m easure an 
autonom ous outcom e domain related to ,but di stinct from ,functioning an d HRQoL over a 4 -
week peri od (Li pton et al . 2009). The i tems assess the domains o f functioning, rapid relief, 
H8H-MC-LAIJ(b) Clinical Protocol Page 42
LY573144consistency, recurrence, and side effects (Serrano et al 2015).  This study  will use the 6-item 
versio n (mTOQ -6) at baseline/first visit with Likerttyperesponse opti onsof Never ( 0 points ); 
Rarely (0 points ); Less than half the time (1 points ); and Half the time or more (2 points ). A 
total score from  0 to 8 is calculated by  [CONTACT_886853] 4of the i tems (
2-hour pain 
freedom, sustained 24
-hour pain relief, co mfortable to m ake plans, and perceived control) which
define categories of acute treatment response :  very poor (0), poor (1-5), moderate (6-7), and 
maximum (8) treatm ent efficacy (Lipton et al . 2015 ).  This quest ionnaire wil l be administered at 
Visit 2.
EQ-5D- 5L:  5-Dimensio ns 5-Levels (EQ-5D- 5L) questionnaire is a widely used, generic 
questionnaire that assesses healt h status (The EuroQol Group 1990 ;Herdman et al. 2011).  This 
is a patient -rated scale.  The questionnaire c onsists of [ADDRESS_1240954] part assesses 
5dimensio ns (mobilit y, self-care, usual act ivities, pain/disco mfort, and anxiet y/depressi on) that 
have 5 possible levels of response ( no probl ems, slight probl ems, m oderate problems, severe 
probl ems, extrem e problems).  This part of the EQ -5D can be used to generate a health state 
index score, which is used to compute qualit y-adjusted life years for utilizat ion in healt h 
economic analyses.  The healt h state index score is cal culated based on the responses to the 
5dimensio ns, providing a single value on a scale from less than 0 (where 0is a healt h state 
equivalent to death; negat ive values are valued as worse than death ) to 1 (perfect healt h), with 
higher scores indicat ing better healt h utilit y.  The second part of the questionnaire consists of a 
visual analog scale on which the pati ent rates their perceived healt h state from 0 ( the worst heal th 
you can imagine ) to 100 ( the best healt h you can imagine ).  The EQ -5D- 5L wil l be captured at 
Visit 2and at 0 and 24 hours postdose during each migraine .
Disability:   Disabilit y will be measured by  [CONTACT_395569] l evel of interference wi th norm al 
activit ies wit h 4 response options including not at all; mild interference, marked i nterference; and 
need co mplete bed rest. This will be evaluated at 0, 0.5, 1, 2 ,4, 6, and 24 h ours postdose during 
each migraine . 
Patient Global Impression of Change (PGIC ):  Patient global impression of change will be 
measured at 2 and 24 hours postdose with a 7-point scale ranging from very much better to very 
much worse during each migraine .
Treatment Satisfaction :  Treatment satisfaction will be evaluated at the EoS visit by 
[CONTACT_660069]’s level of satisfact ion (ranging fro m extremely 
dissatisfied to extremely 
satisfied ); thei r willingness to take this treatment again (ranging fro m strongly  disagree to 
strongly  agree )and if they  would they  recommend this treatm ent to another patient (ranging 
from strongly  disagree to strongly agree ).
9.1.3. Appropriateness of Assessments
The assessments collected during this study are standard and generally recognized as reliable, 
accurate, and relevant.  The study  has 2primary  endpoints.  Pain freedo m at 2hours postdose is 
a recommended primary  endpoint to assess efficacy  of a migraine treatment .  Based on 
regul atory  guidance for consistency  studi es, the other primary  endpoint is consistency  of effect.   
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240955] via eCRF the occurrence and nature of 
each patient ’s preexist ing condit ions, including clinically significant signs and symptoms of the 
disease un der treatm ent in the study .  In addit ion, site personnel  will record any  change in the 
condi tion(s) and any  new condi tions as AEs . Investi gators shoul d record the following via eCRF 
for each AE :  time of onset, time of terminat ion, severit y, and their assessment of the potential 
relatedness of each AE to protocol procedure andinvestigational product.
The invest igator will interpret and document whether or not an AE has a reasonable possibilit y 
of being related to study  treatm ent, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies.
A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure and the AE .
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient ’s investigational product is di scontinued as a result of an AE, study  site personnel  
must report this to Lilly or its designee via eCRF , 
clarifying if possible, the circumstances 
leading to any  dosagemodifications, or discontinuations o f treatm ent.
9.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
H8H-MC-LAIJ(b) Clinical Protocol Page 44
LY573144death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_82340] m ay jeopardi ze the patient or m ay require intervent ion 
to prevent one of the other outcomes listed in the defini tion above.   Examples of 
such m edical events include allergic bronchospasm requiring intensive treatment 
in an em ergency room  or at hom e, blood dy scrasias or convulsions that do not 
resul t in inpat ient hospi [INVESTIGATOR_3094], or the development o f drug dependency or drug 
abuse
All AEs occurring after signing the ICF are recorded in the e CRF and assessed for serious 
criteria.  The SAE reporting to the sponsor begins after the patient has signed the ICF and has 
received invest igational product.  However, if an SAE o ccurs after signing the ICF, but prior to 
receiving invest igational product, the SAE should be reported to the sponsor as per SAE 
reporting requirements and t imelines (see Sect ion 9.2)if it is considered reasonably possibly  
related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_1240956] igator 
awareness o f the event via initiation o f the SAE eCRF .Once the SAE eCRF form is init iated, an 
email is automati cally tri ggered to the Sponsor’s global pat ient safety  depart ment. Investigators 
can contact [CONTACT_886854].If alerts are issued via 
telephone, they  are to be immediately fo llowed wi th official  notificat ionvia co mpletion of the 
SAE eCRF . If the eCRF is unavailable (for example, for system maintenance ) for a peri od of  
time that would compro mise the sites ’abilit y to report an event within [ADDRESS_1240957] igator, and submitted via fax to the S ponsor ’s global patient safet y department. This 
form includes a fax cover page that is pre -popul ated wi th the appropri ate fax number. Serious 
adverse events submitted via the paper method are entered into the eCRF once the database is 
available. The 24- hour notification requirement refers to the init ial SAE information and all 
follow
-up SAE informat ion.Patients with a serious hepat ic AEshoul d have addi tional data 
collected using the eCRF .
Pregnancy ( during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligate d to actively seek AEs or SAEs in patientsonce they  have 
discontinued and/or completed the study  (the patientdisposit ion CRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a patienthas 
H8H-MC-LAIJ(b) Clinical Protocol Page 45
LY573144been dis charged from  the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adver se react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
[LOCATION_002] [ADDRESS_1240958] ive 2001/20/EC and the 
associated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs.  Lilly  has procedures that will be followed for the 
ident ificat ion,recording and expedited reporting of S[LOCATION_003]Rs that are consistent wi th global 
regul ations and the associated detailed guidances.
9.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor qu ality, and to 
facilitate process and product improvements.
Patients will be instructed to contact [CONTACT_81129] a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
9.3. Treatment of Overdose
Refer to the IB.
9.4. Safety
The safet y assessments are described below.
9.4.1. Electrocardiograms
For each patient,a single 12 -lead di gitalECG willbe co llected according to the Schedule o f 
Activities (Secti on 2)as a baseline .  There will be no central reading of ECGs.
Patients m ust be supi[INVESTIGATOR_17044]  [ADDRESS_1240959] 
dose of study treatm ent shoul d be reported to Lilly or its de signee as an AE via e CRF.
9.4.2. Vital Signs
Vital signs will  include body  temperature, bl ood pressure, and pulse.  Blood pressure and pulse 
will be measured in the sitting posit ion prior to bl ood draws , according to the Schedule of 
Activities (Section 2) and fo llowing the study -specific reco mmendat ions included intheManual 
of Operati ons for the study .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240960] dose of study treatment should be reported to Lilly or 
its designee as an AE viaeCRF .
9.4.3. Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 2 ) shoul d be conducted according to the 
Schedule of Act ivities (Secti on 2). 
Lilly orits designee will provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central vendor, if a central vendor is used for the clinical trial.  
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the patientreceives the first dose of study  treatm entshoul d be reported to Lilly or its 
designee as an AE via eCRF .
9.4.4. Other Tests
Columbia Suicide -Severity Rating Scale (C -SSRS):   A scale that captures the occurrence, 
severit y
,and frequency  of suicide -related thoughts and behaviors during the assessment period
(Posner et al. 2011) .  The scale includes suggested questions to solicit the type of informat ion 
needed to determine if a suicide -related thought or behavior occurred.  The C -SSRS is 
administered by  [CONTACT_878700] 1 y ear of pat ient 
care/clinical experience according to the Schedule of Act ivities (Secti on2).  Thetool was 
developed by [CONTACT_886855] ( NIMH
)trial group (T reatm ent of 
Adolescent Suicide Attempters Study ) for the purpose of being a counterpart to the Columbia 
Classificat ion Algorithm o f Suicide Assessment ( C-CASA )categori zation of  suicidal  events . 
Two versions of the C- SSRS will be used:
The screening version will be ad minis tered at Screening/Visit 1
The “since last visit” versio n will be administered at Visit 2 and Visit 4 (at 
2months) and at V6 (EoS)
For thisstudy , the C -SSRS i s adapted for the assessment of the ideat ion and behavior categories 
only.The Intensit y of Ideation and Lethalit y of Behavi or secti ons are rem oved.
The nonleading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS. If a 
suicide-related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collect ion, sites shoul d not change the AE form. If an adverse event i s seri ous or 
leads to di scont inuat ion, thi s is an exception where the SAE and/or AE leading to 
discontinuat ion shoul d be included on the AE form and the process for reportin g SAEs shoul d be 
followed.
Assessment of driving accidents/violations:   In order to further evaluate the impact of 
lasmiditan on driving, an assessment of driving accidents/vio lationswill be conducted by 
[CONTACT_886856] (Secti on2).  
H8H-MC-LAIJ(b) Clinical Protocol Page 47
LY5731449.4.5. Safety Monitoring 
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393].
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, AST ≥3X ULN, ALP ≥2X ULN, or 
elevated TBL ≥2X ULN, liver testing ( Appendix 4 ) should be repeat ed within [ADDRESS_1240961] ion
Addit ional safet y data should be co llected if 1 or more of  the f ollowing condit ions occur: 
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevation of serum  AST to ≥5X ULN on 2 or more consecutive blood tests
elevated serum TBL to ≥ 2X ULN (except for cases of known Gilbert’s 
syndro me)
elevation of serum  ALPto ≥2X ULN on 2 or more consecutive blood tests
patient discont inued fro m treatm ent due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a SAE
9.5. Pharmacokinetics
Not applicable.
9.6. Pharmacodynamics
Not applicable.
9.7. Genetics
9.7.1. Whole Blood Sample for Pharmacogenetic Research
A who le blood sample will be co llected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Section 2)where local regulat ions allow.  
Samples will  notbe used to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Sa mples will be used to investigate variable response to lasmiditan and to 
investigate genet ic variants though t to pl ay a rol e in migraine.  Assessment of variable response 
may include evaluation o f AEs or differences in efficacy.  
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240962] pati ent vi sit for the study , or f or a shorter period if local regulations and/or ethical 
review boards (ERBs)/investigational review boards (I RBs) impose shorter time limits.  This 
retenti on peri od enables use o f new techno logies, response to regulatory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development of 
lasmiditan or after lasmiditan beco me(s) commercially available.
Molecular techno logies are expected to improve during the [ADDRESS_1240963] ion. 
9.8. Biomarkers
Not applicable.
9.9. Medical Resource Utilization and Health Economics
Health Care Resource Utilization and Employment Status :  The Health Care Resource 
Utilizat ion quest ionnaire (HCRU) will be so licited by [CONTACT_529997].  The HCRU consists of [ADDRESS_1240964] ivities, 
given the correlat ion and potential confounding with healt h outcome measure s.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240965] attack, and approximately  800 wi th complete data for 
consistency assessment.  An addit ional 200 pat ients may be rando mized if ther e is an insufficient 
number of patients with co mplete data for consistency assessment.  
Eligible pat ients will be randomized in blinded fashio n in a 1:1:[ADDRESS_1240966] of 2 trea tment sequence groups 
where all patients
receive placebo for 3 attacks and are randomized 1:[ADDRESS_1240967] attack provides >90% power to detect a difference 
in headache pain- free response at 2 hours for assumed true rates of 29% for l asmidi tan 100 m g 
and 19% fo r placebo for the first attack.  The power is expected to be higher for the comparison 
of lasmidi tan [ADDRESS_1240968] of lasmiditan 200 mg versus lasmiditan 
100 m g observed in previous studies. 
For the consistency  primary  endpoint s, assuming 0.3 and 0.2 correlat ion coefficient samong 
multiple attacks for lasmiditan and placebo respectively, and assuming a consistent response rate 
at each attack for lasmiditan and placebo, a sample size of 260 patients per treatment arm 
provi des >90 % power for 2 -hour headache pain-free consistency for the 200 -mg dose arm and 
nearly90% power for consistency  in the 100 -mg dose arm. 
10.2. Populations for Analyses
For purposes of analysis, the populat ions are defined below.  For efficacy analyses, patients a re 
evaluated by [CONTACT_886857]. For safet y analyses, p atients 
will be analyzed according to the treatment group they actually received ,which will generally be 
the sam e as randomized treatment unless there is an error .  
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240969] moderate pain severity
with any  postdose pain severity assessments at or before 2 hours postdose .
ITT consistency All randomized patients who experience a sufficient number of successes or  
failures (defined in Section 10.3.1 ) during ITT -evaluable attacks for any of the 
consistency analyses . 
mITT consistency All randomized patients who experience a sufficient number of successes or  
failures (defined in Section 10.3.1 ) during mITT -evaluable attacks for any of the 
consistency analyses .
Safety All randomized patients who take at least 1 dose of study drug, regardless of 
whether o r not they undergo any  study  assessments . 
Abbreviations :  ITT = intent -to-treat; mITT = modified intent -to-treat .
10.3. Statistical Analyses
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee. The statistical 
analysis plan (SAP) will be finalized and approved prior to unblinding of treatment at database 
lock.
Efficacy analyses will be conducted on the ITT populat ion.  Thi s set includes all rando mized 
patients who use at least [ADDRESS_1240970] mild pain severit y with any postdose pain severi ty asssessments at or before 2 
hours postdose .  Patients will be evaluated by  [CONTACT_886858] .  
Consistency analys es will  be conducted on the ITT consistency  popul ation.  Th isset includes all 
rando mized patients who experienced a sufficient number of successes or failures during ITT -
evaluable attacks for any  of the co nsistency analyses . The “s ufficient number ” is defined 
different ly for the 2endpoints related to consistency (that is,2 out of3 attacks and 3 out of 4
attacks ):  
Two of 3:  To evaluate the [ADDRESS_1240971] 2 or 3 ITT -evaluable attacks .
H8H-MC-LAIJ(b) Clinical Protocol Page 51
LY573144Three of 4:  To evaluate the [ADDRESS_1240972] 3successes or 2
failures during ITT -evaluable attacks .  
For analyses where mITT population s are specified, the definit ionsarethe same as for ITT 
popul ations,except based on mITT -evaluable attacks.
Tests of the primary and gated secondary  endpo ints, as specified in the SAP, will be conducted at 
a 1-sided significance level o f 0.025; tests of all other endpoints will be conducted at a 2-sided 
significance l evel of 0.05.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature o f the protocol .  Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed appropri ateas described in the Statist ical Analysis Plan (SAP) .
10.3.2. Treatment Group Comparability
[IP_ADDRESS]. Patient Disposition
Patient disposi tion will be summarized by [CONTACT_1570] .  Reasons for discont inuat ion for all 
patients will  be tabulated for treatmen t groups, and comparisons between treatment groups will 
be assessed by  [CONTACT_3493]’s exact test.
[IP_ADDRESS]. Patient Characteristics
Patientcharacterist ics will be summarized by [CONTACT_6654]. Summaries will 
include descript ive statist ics for continuous m easures and for categorical measures (sample size, 
frequency ,and percentages). Treatments will be compared by [CONTACT_886859] o f variance 
techniques for continuous data and Pearson’s chi -square or Fisher’s exact test for categorical 
data. 
The results of th ese tests will be used in a descript ive way to highlight potential imbalances 
between the treatment groups. Patient characterist ics may include, but are not limited to :  age, 
gender, race/ethnicit y, height, weight, body mass index , and migraine history . 
Patientcharacterist ics will be summarized on all study populations.
[IP_ADDRESS]. Concomitant Therapy 
Frequency and percentages will be calculated by [CONTACT_886860]. 
Treatments will be compared using Fisher’s exact test. 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240973] ics (n, mean, SD, median, minimum and maximum).
Ediary  com pliance will be summarized within each treatment group and each attack group.
10.3.3. Efficacy Analyses
[IP_ADDRESS]. Primary Analyses
The firstprimary object ive of this study  is to assess the efficacy o f lasmiditan 200mg and 
lasmiditan 100 mg on migraine headache pain freedom .  The primary measurement is the 
proporti on of  patients having pain free dom (defined as mild, moderate, or severe headac he pain
beco ming none) at [ADDRESS_1240974] attack.   This analysis will be performed on 
the ITT populat ion.
The second primary  objective of thi s study  is to assess the consistency  of efficacy o f lasmiditan 
200 m g and lasmidi tan 100 m g on mi graine headache pain freedo m.  The primary measurement 
is the proporti on of  patients having pain free dom (defined as mild, moderate, or severe headache 
pain beco ming none) at [ADDRESS_1240975] 1of the 4hypothesis tests 
specified above ( lasmidi tan 200 mg or 100 mg compared with placebo on migraine headache 
pain freedo m, lasmidi tan 200 mg or 100 mg compared with placebo on consi stency  of efficacy) 
is statistically  significant . 
Logist icregressio nwith categori cal term s for treatment and geographi c regi on will be used to 
statist ically evaluate the proportions of pat ients achieving migraine headache pain freedo min 
first attack for lasmidi tan treatm ent groups versus placebo and also in the consistency analyses 
comparing lasmidi tan treatm ent groups versus placebo .  In order to control for overall type I 
error, the primary analyses wil l be tested using a multiple comparisons procedure that preserves 
overall t ype I error at 1 -sided alpha level o f 0.025.  Thismultiple co mpar isons procedure will be 
defined in the SAP ,which contains the graphic scheme and weights for alpha propagation . 
As a sensit ivity analysis, the primary  and gated secondary  efficacy en dpoint swill be repeated on 
the mITT popul ation.Addit ionally, the consistency  endpoints will be repeated in the mITT 
consistency populat ion.
[IP_ADDRESS]. Secondary Analyses
The secondary  measures wi ll be analyzed using the ITT and ITT consistency population s.
Logist ic regressio nwill be used to statistically evaluate the proporti ons of response among 
lasmiditan gro ups and placebo . The model contains categori cal terms for treatment and
geographi c reg ion.The comparison swill be between lasmiditan groups versus placebo at first 
attack and 2 out of 3 consistency endpo ints.  The comparisons will be between lasmiditan groups 
H8H-MC-LAIJ(b) Clinical Protocol Page 53
LY573144versus control group for the 3 out of 4 attacks consistency endpo ints.  For continuous endpo ints, 
analysis of variance ( ANOVA )or analysis of covari ance ( ANCOVA )will be used to assess the 
effect of lasmiditan .  The raw total score or change fro m baseline of total  score are d ependent 
variable s.  The m odel includes fixed categorica l effect of treatm ent and geographic region and 
baseline as covariate .  The primary co mpar ison will be between the lasmiditan group sversus 
placebo.
In order to control for overall type I error, the primary  and a subset of secondary objectives will 
be gated as described in the SAP.  The gated secondary  analyses will be tested using a multip le 
comparisons procedure that preserves overall type I error at 1-sided al pha level  of 0.025.  If any 
of the null hypothes esarerejected for the primary endpo ints, the gated secondary endpo ints will 
be tested according to the multiple co mpar isons procedure defined in the SAP . 
[IP_ADDRESS]. Tertiary/Exploratory Analyses 
Logist ic regressio nwill be used to statistically evaluate the proporti ons am ong lasmidi tan groups 
and placebo g roup for expl oratory  endpoints .  The primary  com parison will be between 
lasmiditan groups versus placebo at first attack and [ADDRESS_1240976] of treatm entand 
geographi c regi on and baseline as covariate.
10.3.4. Safety Analyses
[IP_ADDRESS]. Treatment -Emergent Adverse E vents
Treatment -emergent adverse events are defined as the reported AEs that first occurred or 
worsened during the postbaseline phase co mpared with the baseline phase. For each TEAE, the 
reported severit y level o f the event (mild, moderate, or severe) will be d etermined by [CONTACT_886861][INVESTIGATOR_3078] n. The Medical Dict ionary for Regul atory  Activities (MedDRA) Lowest Level
Term  (LLT) will  be used in the treatm ent-emergent com putati on. Foreach patient and TEAE, 
the maximum severit y for the MedDRA level being di splayed (preferred term, High Level  Term , 
or system  organ cl ass [SOC ]) is the m aximum postbaseline severit y observed from  allassociated 
LLTs mappi[INVESTIGATOR_355690]. An AE wi th time ofonset wi thin 48 hours after a dose of 
study  drug, or an event th at worsens in intensit y within 48 hours aftera dose of study  drug will 
be considered a TEAE .  An AE that occurs in the interval after 48 hours of dosing unt il 
EoS/Visit 6will not be considered a TEAE.   For events that are sex -specific, the denominator 
and co mputation of the percentage will include only patients from  the specific sex.
Frequency counts and percentages will be presented for subjects with TE
AEs within each SOC
and preferred t erm, separated by [CONTACT_2939] .  Both subjects ever experiencing anevent as 
well as total events will be presented.  Descript ive statist ics will also be calculated for each 
treatm ent arm  forAE relat ionship and AE severi ty.  If mu
ltiple intensit ies are reported for a 
given TEAE for a subject, the most severe intensit y will be counted .  Analyses will be perform ed 
by [CONTACT_886862].  For the con trol arm, placebo and 
lasmiditan 50 mg will be evaluated separately. Other details can be found in the SAP.
H8H-MC-LAIJ(b) Clinical Protocol Page 54
LY57314410.3.4.2. Columbia- Suicide Severity Ratin g Scale 
Suicide-related thoughts and behaviors and self- injuri ous behavior with no suicidal intent, based 
on the C -SSRS, will be listed by  [CONTACT_4676].
[IP_ADDRESS]. Vital Signs
The number and percentage of patients meet ing criteria for treatment -emergent abnorm alities in
vital signs and wei ght at any  time during study  will be summarized by [CONTACT_1570] . 
[IP_ADDRESS]. Labs
By-patientlistings of clinical laboratory  data will include indicat ions of values that are outside 
the reference ranges, and values that are clinically significant .  Shift tables describing 
out-of-reference range shifts wi ll be provi ded for clinical laboratory  test results from 
Screening/Visit 1 to EoS/Vi sit 6, as appropriate by [CONTACT_435344].
[IP_ADDRESS]. Assessment of Driving Accidents
Assessment of accidents/vio lations wil lbe listed by [CONTACT_344852] .
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Not applica ble.
10.3.6. Evaluation of Immunogenicity 
Not applicable.
10.3.7. Other Analyses
[IP_ADDRESS]. Health Economics 
Mean HRQoL score in each group for 24
-hour MQoLQ and change fro m baseline for MIDAS 
(item scores and total score), EQ -5D- 5L, and the disabilit y itemwill be analyzed. In addit ion, 
categori cal analyses will be performed for disabilit y and PGIC . Changes in healt h care resource 
utilizat ion and emplo yment status will also be evaluated .  Details are summarized in the SAP.
[IP_ADDRESS]. Subgroup Analyses 
Subgroup analyses for the primary efficacy  and consistency endpo intsand pain relief at 2 hours 
will include the fo llowing subgroup vari ables:
age
sex
weight
racial origin
previous response to triptan 
geographi cal regi on
cardi ovascular risk factors
migraine headaches t reated more than 4 hours after onset 
Addit ional details are available in the SAP.
H8H-MC-LAIJ(b) Clinical Protocol Page 55
LY57314410.3.8. Interim Analyses
No interim analyses are planned for this study .  If an unplanned interim analysis is deemed 
necessary , the appropri ate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.
H8H-MC-LAIJ(b) Clinical Protocol Page 56
LY57314411. References
Adelborg K, Szépligeti SK, Holland -Bill L, Ehrenstein V, Horváth -Puhó E, Henderson VW, 
Sørensen HT. Migraine and risk of cardiovascular diseases: danish populat ion based matched 
cohort study . BMJ . 2018; 360(10):k96. 
Bigal ME, Kurth T, Santanello N, Buse D, Gol den W, Robbins M, Lipton RB . Migraine and 
cardi ovascular di sease: a populat ion-based study . Neur ology .2010;74(8):628 -635.
Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby [CONTACT_33263], Lipton 
RB. Di sabili ty, HRQoL and resource use among chronic and epi[INVESTIGATOR_160343]: results 
from the Internat ional Burden of Migraine Study (IBMS). Cephalalgia .2011;31(3):[ADDRESS_1240977] of 
chronic and epi[INVESTIGATOR_17730]: results from the American Migraine Prevalence and Prevention 
study . Headache. 2012;52(1):3 -17. 
Dodi ck D, Li pton RB, Martin V , Papademetriou V, Rosamond W, MaassenVanDenBrink A, 
Loutfi H, Welch KM, Goadsby  [CONTACT_33263], Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith 
TR, Purdy  RA, Sai ers J. Triptan Cardi ovascular Safet y Expert Panel . Consensus statem ent: 
cardi ovascular safet y profile of tri ptans (5 -HT1B/1D agonists) in the acute treatment of 
migraine. Headache .2004;44(5):414 -425.
Committee for Medicinal Products for Human Use (CHMP) . Guideline on clinical invest igation 
of medicinal products for the treatment of migraine (Document) Document London, 24 
January  2007 European Medicines Agency  (EMA)
http://www.ema.europa.eu/docs/en_GB/document_library /Scient ific_guideline/2009/09/WC50
0003481.pdf .
[EuroQol ] The EuroQol Group. EuroQol --a new f acility for the measurement of healt h-related
qualit y of life. Health Policy . 1990;16(3):199 -208.
Goadsby  [CONTACT_33263]. The vascular theory  of migraine —a great story  wrecked by  [CONTACT_886863]. Brain.
2009;132(Pt 1):6 -7.
Hartm aier SL, Santanello NC, Epstein RS, Silbers
tein SD. Development of a brief 24- hour 
migraine -specific qualit y of life questionnaire. Headache .1995;35(6):320 -9. 
Herdm an M, Gudex C, Llo yd A, Janssen MF, Kind P, Parkin D, Bonsel G, Badia X.
Development and preliminary  testing of the new five -level versi on of EQ-5D (EQ -5D- 5L).
Qual Life Res . 2011;20(10):1727- 1736.
Ho AP, Dahlo f CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, 
Lines CR, Ho TW. Rando mized, controlled trial o f telcagepant over 4 migraine attacks. 
Cephalalgia. 2010;30(12):[ADDRESS_1240978] IJM, Skingle M, Whalley  ET. Serotonin and 
migraine. Ann NY Acad Sci .1990; 600(1) :587-598. 
[IHS] International Headache Societ y, Headache Classificat ion Subc ommittee. The International 
Classificat ion of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1 –211.
H8H-MC-LAIJ(b) Clinical Protocol Page 57
LY573144[IHS] International Headache Societ y,Clinical Trials Subco mmittee , Tfelt-Hansen P, Pascual  J, 
Ramadan N, Dahlö f C, D'Amico D, Diener HC, Hansen JM, Lanteri -Minet M, Loder E, 
McCrory  D, Pl ancade S, Schwedt T . Guidelines fo r controlled trials of drugs in migraine: 
Third edi tion. A gui de for invest igators. Cephalalgia .2012; 32 (1): 6–38.
Labast ida-Ramirez A, Rubio -Beltran E, Garrel ds IM, Haanes K A, Chan K Y, Kovalchin 
J,Johnson KW, Danser AHJ , Villal onC
M, MaassenVanDenBrink A.Lasmiditan inhibit s 
CGRP Release in the mouse trigemino vascular system , abstract PO -02-172. Cephalalgia . 
2017;37([ADDRESS_1240979] ):362 -363.
[Lilly ] Eli Lilly and Com pany . April 2018. Invest igator’s Brochure for L Y573144.
Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examinat ion of unmet treatment needs 
among persons wit h epi[INVESTIGATOR_39751] c migraine: results of the american migraine prevalence and 
prevent ion (AMPP) study . Headache . 2013;53(8):[ADDRESS_1240980] ive acute treatment of 
epi[INVESTIGATOR_886834] -onset chronic migraine. Neurology .
2015;84(7):[ADDRESS_1240981] ionnaire. Cephalalgia
.2009;29(7):751 -759.
Lipton RB, Bi gal ME, Stewart, WF. Clinical tr ials of acute treatm ents for migraine including 
multiple attack studies of pain, disabilit y, and heal th-related qualit y of life. Neurology.
2005;65([ADDRESS_1240982] 4):S50 -S58.
Mitsikostas DD, Tfelt -Hansen P. Targeting to 5 -HT1F receptor subtype for migraine trea tment: 
lessons fro m the past, implications for the future. Cent Nerv Syst Agents Med Chem . 
2012;12(14):241 -249.
Posner K, Brown G, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ .The Co lumbia -Suicide Severi ty Rating Scale: init ial 
validit yand internal  consistency findings from three mult isite studies wit h adolescents and 
adults. Am J Psychiatry .2011;168(12):1266 -1277.
Ramadan NM, Skljarevski V, Phebus LA, Johnson KW. 5- HT1F recep tor agoni sts in acute 
migraine treatment: a hy pothesis. Cephalalgia. 2003;23(8):776 -785.
Santanello NC, Polis AB, Hartmaier SL, Kramer MS, Block GA, Silberstein SD . Improvement 
in migraine -specific qualit y of life in a clinical trial o f rizatriptan. Cephal algia .
1997;17(8):867 -72; di scussio n 800.
Santanello NC, Hartm aier SL, Epstein RS, Silberstein SD . Validat ion of a new qualit y of life 
questionnaire for acute migraine headache. Headache .1995;35(6):330 -337.
Serrano D, Buse DC, Manack Adams A, Reed ML, Li pton RB. Acute treatment optimization in 
epi[INVESTIGATOR_33176]: results of the American Migraine Prevalence and Prevent ion 
(AMPP) Study . 
Headache .2015;55(4):502 -518..
Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. Cephalalgia
.
2013;33(5):289 -290.
H8H-MC-LAIJ(b) Clinical Protocol Page 58
LY573144Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine 
Disabili ty Assessment (MIDAS) Questionnaire to assess headache -related di sabili ty. 
Neurology .2001;56(Suppl 1):S20–S28 .
Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawy er J. Reliabilit y of the migraine 
disabili ty assessment score in a populat ion-based sam ple of headache sufferers. Cephalalgia.
1999;19(2):107 -114.
Tfelt-Hansen PC, Diener, HC. Why should American headache and migraine patients still be
treated with butalbital -containing medicine? Headache . 2012;52(4):672 -674.
Woldeamanuel YW, Cowan RP.Migraine affects 1 in 10 people worldwide featuring recent rise: 
A systematic review and meta -analysis of co mmunit y-based s tudies invo lving 6 millio n 
participants. J Neurol Sci. 2017;372:307 -315.
H8H-MC-LAIJ(b) Clinical Protocol Page 59
LY57314412. Appendices
H8H-MC-LAIJ(b) Clinical Protocol Page 60
LY573144Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AEcan therefore be any unfavorable and 
unint ended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analy sis of covariance
ANOVA analy sis of variance
AST aspartate aminotransferase
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not.
A double -blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received.
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or eff ectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
C-SSRS Columbia Suicide S everity Rating Scale
CV cardiovascular
ECG electrocardiogram
EDC early  discontinuation
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240983]
FSH follicle -stimulating hormone
GCP good clinical practice
HCRU Health Care Resource Utilization
HRQ oL Health-Related Qu ality of Life
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IHS International Headache Society
Informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of th e study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
[CONTACT_3553] a written, signed and dated informed consent form .
INR internatio nal no rmalised ratio
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an una uthorized indication, or marketed products used to 
gain further information about the authorized form.
IRB institutional review board
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_886864] a patient (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as mem bers of that group irrespective of their compliance to the 
planned course of treatment.
IVRS/IWRS interactive voice -response sy stem/interactive web -response system
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240984]
mITT modified intention to treat 
MQoLQ 24-Hour Migraine Quality of Life Questionnaire
mTOQ -
6 Migraine Treatment Optimization Questionnaire
PGIC Patient Global Impression of Change
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
QoL quality  of life
SAE serious adverse event
SAP Statistical Analysis Plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TBL total bilirubin level
TEAE Treatment -emergent adverse event:  An AE with time anddate of onset on or within [ADDRESS_1240985] upper limit of normal
WOCBP women of child -bearing potential
H8H-MC-LAIJ(b) Clinical Protocol Page 63
LY573144Appendix 2. Clinical Laboratory  Tests 
Clinical Laboratory Tests
Hematology a,b Clinical Chemistry a,b
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, nonfasting
Urinalysis a,b Albumin
Specific gravity Cholesterol
pH Creatine kinase (CK)
Protein
Glucose Pregnancy Test (females only) c
Ketones Serum pregnancy
Blood Urine pregnancy test (local)
Urine leukocyte esterase
Serum follicle -stimulating hormone ( FSH )c
Urine drug screen
Stored Samples 
Pharmacogenetic sample (genetic sample/DNA)
Abbreviations:  DNA = deoxyribonucleic acid; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated laboratory.
bResults will be confirmed by [CONTACT_266479].
cPregnancy tests to be assessed in women of child -bearin g potential; FSH to be assessed as appropriate according 
todetails in Inclusion Criterion #7 .
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240986] igator is responsible for:
ensuring that the patient understands the nature of the study , the potential risks 
and benefits of participat ing in the study , and that their parti cipat ion is 
voluntary
ensuring that informed consent is given by [CONTACT_57996].  
This includes obtaining the appropriate signatures and dates on the informed 
consent for m (ICF) pri or to the performance of any  protocol  procedures and 
prior to the administra tion of  investigational product
answering any quest ions the pati ent m ay have throughout the study  and 
sharing in a t imely manner any  new informat ion that m ay be relevant to the 
patient’s willingness to continue his or her participation in the study
ensuring that a copy  of the ICF is provi ded to the participant or the 
participant’s l egal representative and is kept on file
ensuring that the medical record includes a stateme nt that wri tten inform ed 
consent was obtained before the participant was enrolled in the study  and the 
date the written consent was obtained.  The authorized person obtaining the 
inform edconsent m ust al so sign the ICF
Appendix 3.1.[ADDRESS_1240987] (ERB) was properly  consti tuted and convened as required by [CONTACT_126171] (ICH) guidelines and other applicable laws and regulations.
Docum entati on of  ERB approval  of the protocol and the I CF must be provided to Lilly  before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by [CONTACT_41429], before it is used at the invest igative site(s).  All ICFs 
must be compliant wi th the ICH gui deline on Good Clinical Pract ice (GCP).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
H8H-MC-LAIJ(b) Clinical Protocol Page 65
LY573144the protocol and related amendments and addenda, current Invest igator 
Brochure (IB) and updates during the course of the study
inform ed con sent f orm
other rel evant docum ents (for example, curricula vitae, advertisements)
Appendix 3.1. 4. Regulatory Considerations
This study  will be conducted in accordance wit h the protocol and with the:
consensus ethics principles derived fro m internat ional et hics guidelines, including 
the Decl aration of Helsinki and Council forInternational Organizati onsof
Medical Sciences Internat ional Ethi cal Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party.
Appendix 3.[ADDRESS_1240988] igators in this clinical trial should be neuro logists, headache specialists, or other specialists 
with experi ence in headache clinical trials and treating migraine patients.
Appendix 3.1. 6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading the protocol , each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Appendix 3.1. 7. Final Report Signature
[CONTACT_221083], indic ating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
An invest igator selected by  [CONTACT_530006].  If 
this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_229511].
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
H8H-MC-LAIJ(b) Clinical Protocol Page 66
LY573144sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instruction on the protocol, the complet ion ofthe CRFs, and 
study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact [CONTACT_129237], tel ephone, and/or fax
review and evaluate CRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives will periodically check a sample of the patientdata 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_47551] i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators wi ll be given noti ce before 
an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regul atory  agencies, and applicable ERBs with direct access to original source 
docum ents.
Appendix 3.2.1. Data Capture System
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_92363] -provided electronic data capture system.
In thi s study , pati ent data will be collected direct ly via an electronic patient -reported outcome 
(ePRO) eDiary as part of an ePRO/Clinical Outcome Assessment (COA) sy stem . This will 
include quest ions on headache pain, migraine associated symptoms, dosing, and use of rescue or 
recurrence medication.  Pati ent-rated scales/ quest ionnaires will also be collected di rectly via the 
ePRO eDiary(see Appendix 7 ).  Data entered into the ePRO/COA system will serve as the 
source data .
If ePRO records are stored at a third party  site, investi gator si tes will  have continuous access to 
the source documents du ring the study  and will  receive an archival copy  at the end of the study  
for retenti on.
Any data for which the ePRO instrument record will serve to collect source data will be 
ident ified and documented by [CONTACT_140842]’s study file .
Electronic casereport form data will be encoded and stored in a clinical trial database .  Data 
managed by  a central  vendo r, such as laboratory  test data , will be stored electronically in the 
central  vendor’s database system.  Data will subsequent ly be transferred from the central  vendor 
to the Lilly data warehouse.
Any data for which paper documentation provided by [CONTACT_229512] i dentified and documented by  [CONTACT_92366]’s study  file.  Paper 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240989] igator, or the ERB of the study  
sitejudges it necessary for medical, safety , regul atory , or other reasons consistent with 
applicable laws, regulat ions, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be di scontinued if Lilly judges it necessary for medical, safet y, regul atory , or 
other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3.4. Publication Policy
The publicat ion policy for Study  H8H -MC-LAIJis described in the Clinical Trial Agreement.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240990]
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspi[INVESTIGATOR_82355]; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
H8H-MC-LAIJ(b) Clinical Protocol Page 69
LY573144Appendix 5. Diagnostic Criteria for Selected Migraine 
Types 
International Classification of Headache Disorders -3 Diagnosis and Diagnostic C riteria per 
International Headache Society 2018
1.1 Migraine without aura
Previously used terms :  Commo n migraine; hemicranias simplex
Descript ion:Recurrent headache disorder manifesting in attacks last ing 4 –[ADDRESS_1240991] ivity and associat ion with nausea and/or 
photophobi a and phonophobia .
Diagnostic cri teria:
A. At least five attacks fulfilling criteria B –D
B. Headache attacks lasting 4 –72 hours (when untreated or unsuccessfully treated)
C. Headache has at least two of the following four characterist ics:
1. unilateral location
2. pul sating qualit y
3. moderate or severe pain intensit y
4. aggravation by [CONTACT_707112] (e.g. walking 
or climbing stairs)
D. D uring headache at least one of the fo llowing:
1. nausea and/or vomit ing
2. photophobia and phonophobia
E. Not better accounted for by  [CONTACT_25443] -
3diagnosis
1.2 Migraine with aura
Previously  used terms: Classic or cl assical migraine; ophthalmic, hemiparaesthet ic, hemiplegic 
or aphasic migraine; migraine ac compagnée; complicated migraine
Descript ion: Recurrent attacks, last ing minutes, of unilateralfully reversible visual, sensory or 
other central nervous sy stem  symptom s that usually  devel op gradu ally and are usually fo llowed 
by [CONTACT_287458] .
Diagnostic cri teria:
A. At least two attacks fulfilling criteria B and C
H8H-MC-LAIJ(b) Clinical Protocol Page 70
LY573144B. One or more of the fo llowing fully  reversible aura symptom s:
1. visual
2. sensory
3. speech and/or langu age
4. motor
5. brainstem
6. retinal
C. At l east three of the following six characterist ics:
1. at l east one aura symptom spreads gradually  over ≥5 minutes
2. two or m ore aura symptom s occur in successio n
3. each individual aura symptom lasts 5–[ADDRESS_1240992] one aura symptom is positive
6. the aura is acco mpanied, or followed wit hin 60 minutes, by  [CONTACT_12704]
D. Not better accounted for by [CONTACT_25443] -3 diagnosis
1.2.1 Migraine with typi[INVESTIGATOR_886835]
:  Migraine wi th aura, in which aura consists of visual and/or sensory  and/or 
speech/language symptoms, but no motor weakness, and is characterized by [CONTACT_287459], duration of each symptom no longer than 1hour, a mix of posit ive and negative 
featur es and complete reversibilit y
Diagnostic cri teria:
A. Attacks fulfilling criteria for 1.2 Migraine with aura and criterion B below
B. Aura with both of the fo llowing: 
1. fully reversible visual, sensory  and/or speech/ language symptoms 
2. no motor, brainstem or retinal symptoms.
[IP_ADDRESS]  Typi[INVESTIGATOR_886836]:  Migraine wi th typi[INVESTIGATOR_886837] [ADDRESS_1240993] ics.
Diagnostic cri teria:
A. Attacks fu lfilling criteria for 1.2.1 Migraine with typi[INVESTIGATOR_160361] B below
H8H-MC-LAIJ(b) Clinical Protocol Page 71
LY573144B. Headache, with or without migraine characteristics, accompanies or fo llows the aura 
within 60 minutes.
[IP_ADDRESS]  Typi[INVESTIGATOR_886838]:  Migraine wi th typi[INVESTIGATOR_886839].
Diagnostic cri teria:
A. Attacks fulfilling criteria for 1.2.1 Migraine with typi[INVESTIGATOR_160361] B below 
B. No headache acco mpanies or fo llows the aura wi thin 60 min utes.
1.3 Chronic migraine
Descript ion: Headache occurring on ≥15 or m ore days/m onth for m ore than three m onths, 
which, on at least eight day s/month, has the features of migraine headache.
Diagnostic cri teria:
A. Headache (migraine -like or tensio n-type-like) on 15 days/m onth for >[ADDRESS_1240994] five attacks fulfilling criteria B –D for 1.1 
Migraine wi thout aura and/or criteria B and C for 1.2 Migraine wit h aura
C. On ≥8 days/m onth for >3 months, fulfilling any of the following:
1. cri teria C and D for 1.[ADDRESS_1240995] ics of the headache may change not only fro m day 
to day  but even within the same day . Such patients are extremely difficult to keep 
medicat ion
-free in order to observe the natural history  of the headache. In this si tuation, attacks 
with and those wi thout aura are both counted, as are both migraine -like and tensio n-type-like 
headaches (but not secondary  headaches) .
H8H-MC-LAIJ(b) Clinical Protocol Page 72
LY573144Appendix 6. Medication Overu se Headache Diagnostic 
Criteria
International Classification of Headache Disorders -3 Diagnosis and Diagnostic Criteria per 
International Headache Society 2018:
[A] Headache occurring on ≥15 days/month in a pat ient wi th a pre -exist ing 
headache disorder
[B] Regular overuse for >3 months o f one or m ore drugs that can be taken for 
acute and/or symptomat ic treatment of headache (see notes 1 to 3 below)
[C] Not better accounted for by  [CONTACT_25443] -3 diagnosis .
Notes:
[1] Patients shoul d be coded for one or more subty pes of  8.2 Medication -overuse 
headache according to the specific medicat ion(s) overused and the criteria for 
each below. For example, a patient who fulfils the criteria for 8.2.2 Triptan -
overuse h eadache and the criteria for one of the subforms of 8.2.3 Non-opi[INVESTIGATOR_665720] -overuse headache shoul d receive both these codes. The except ion 
occurs when pat ients overuse combinat ion-analgesic medicat ions, who are 
coded 8.2.5 Combination- analgesic -overus e headache and not according to 
each constituent of the combinat ion-analgesic medicat ion.
[2] Patients who use mult iple drugs for acute or symptomat ic treatment of 
headache may  do so in a manner that constitutes overuse even though no 
individual drug or cl ass of drug is overused; such patients should be coded 
8.2.6 Medication -overuse headache attributed to multiple drug classes not 
individually overused .
[3] Patients who are cl early  overusing m ultiple drugs for acute or symptomatic 
treatm ent of headache but cannot give an adequate account of their names 
and/or quantit ies are coded 8.2.[ADDRESS_1240996] all cases, this necessi tates diary  follow-up.
H8H-MC-LAIJ(b) Clinical Protocol Page 73
LY573144Appendix 7. eDiary  Assessments
eDiary Assessment for all attacks treated with study 
drug0h 0.5h 1h 2h 4h 6h 24h 48h
Headache severity
(0 = no pain, 1 = mild pain, 2 = moderate pain, and 
3 =severe pain)X X X X X X X X
Presence or absence (yes or no) of accompanying 
symptoms: photophobia, phonophobia ,nausea, and 
vomitingX X X X X X X X
Select from the accompanying symptoms present (nausea, 
phonophobia or photophobia only) which on e is the most 
bothersome X
Time at which headache relief became meaningful  X
Time at which they become headache pain -free X
MQoLQ X
EQ-5D-5L X X
Disability X X X X X X X
PGIC X X
Abbreviations:  eDiary = electro nic diary ; EQ -5D-5L = EuroQol 5 Dimension 5 Level; h = hours; MQoL Q= 24-
Hour Migraine Quality of Life Questionnaire; PGIC = Patient Global Impression of Change .
H8H-MC-LAIJ(b) Clinical Protocol Page 74
LY573144Appendix 8. Protocol A mendment H8H-MC-LAIJ(b)
Summary
Overview
Protocol H8H -MC-LAIJ (Randomized Controlled Trial of Lasmiditan Over Four Migraine 
Attacks [CENTURION]) has b een amended.  The new protocol is indicated by  [CONTACT_507980] 
(b) and will be used to conduct the study  in place of any preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are summarized in 
the following bullets and in more detail in the subsequent table:
Updated protocol tit le to include the nam e “CENTURION.”
Modified descript ion of endpoints associated with analyses o f first attack for 
the subpopulat ion of tri ptan nonresponders in objectives sect ion.
Clarified inform ation about C -SSRS , specifically noting that a short form of 
the scale is being used and clarifying administration of the self-harm 
supplement and self -harm  follow-up formsin the Schedule o f Activities.
Clarified that driving assessments areconducted by [CONTACT_8786] .
Clarified that repeat laboratory  testi ng outsi de a scheduled visit may be 
conducted in the event of abnormal laboratory  findings .
Updated names and definit ions of analysis populatio ns for consistency  with 
statist ical analysis plan approved before first patient visit (ITT popul ations) or 
for consistency with studies this study  may be compared wi th (mITT 
popul ations).  Updated related descript ions of analyses for clarit y.
In addit ion, some minor points were clarified throughout, and grammat ical 
errors and ty pographical error s were corrected. 
H8H-MC-LAIJ(b) Clinical Protocol Page 75
LY573144Amendment S ummary for Protocol H8H-MC-LAIJAmendment ( b)
Section # and Name [CONTACT_344380], and
Section 1, Synopsis, Title of StudyCENTURION added to protocol title. Added to provide easy study identification for 
publicatio ns.
Section 1, Synopsis, Objectives/Endpoints
(and Section 4, Objectives and Endpoints)Modified description of endpoints associated with 
analy ses of first attack for the subpopulation of 
triptan nonresponders . To align with gating strategy described in statistical 
analy sis plan.
Section 1, Synopsis, Statistical Analysis subsection Definitio n of ITT population was updated.   Aligned with Version [ADDRESS_1240997] -patient -visit.
Descriptio n of consistency analy ses was updated.  Clarified.
Section 2, Schedule of Activities Rows /footnotes added regarding C-SSRS Updated to align with recommendations of Lilly 
Psychobehavioral Working Group; no changes to 
actual procedure .
Note about additional lab testing occurring outside 
scheduled visits added to footnote b.Added to make existing procedure more apparent 
to sites.
Section 6.2, Exclusion Criteria In exclusion [18], added cross -reference to
Appendix 6. Added so that cross -references to both applicable 
appendices were included.
Section 9.4.4, Other Tests Added text to specify use of short ened version of 
the C -SSRS .Updated to align with recommendations of Lilly 
Psychobehavioral Working Group; no changes to 
actual procedure .
Added text to indicate that driving assessments are 
conducted by [CONTACT_8786].Clarifi edexisting procedures.
Section 10.2, Populations for Analysis Updated names and definitions of analysis 
populatio ns; added mITT consistency population .  Updated for consistency with statistical analysis 
plan approved before first patient visit (ITT 
populatio ns); or with studies this study may be 
compared with (mITT populations).
Section 10.3.1, General Statistical Considerations Updated descriptions of efficacy populations, 
particula rly definitio n of sufficient attacks to be 
included in consistency analyses.Updated for clarity and for consistency with 
changes in Section 10.2
Section [IP_ADDRESS], Primary Analyses Simplified description of sensitivity analyses by 
[CONTACT_886865]. Added analysis of 
consistency endpoints in mITT consistency 
populatio n.Modified to meet submission needs.
H8H-MC-LAIJ(b) Clinical Protocol Page 76
LY573144Amendment Summary , continued
Section # and Name [CONTACT_19523] [IP_ADDRESS], Primary Analyses
Section [IP_ADDRESS], Secondary Analyses
Section [IP_ADDRESS], Tertiary/Exploratory AnalysesClarified that geographic region will be included in 
analy sis models (not country).Aligned with statistical analysis plan.
Appendix 1, Abbreviations Updated TEAE definition to note that treatment -
emergent is limited to the 48 hours after dosing. Updated for consistency with statistical analyis 
plan.
Appendix 6, Medication Overuse Headache 
Diagnostic CriteriaAdded source for criteria. Clarification; no change to criteria.
H8H-MC-LAIJ(b) Clinical Protocol Page 77
LY573144Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
For m ost secti ons, only  the sentences or paragraphs with deletions or additions have been 
included; ellipses may be used to take the place of material that did not change.
Title page, title
Protocol H8H-MC-LAIJ(ab)
Randomized Controlled Trial of Lasmiditan Over Four
Migraine Attacks (CENTURION)
1. Synopsis , Title of Study
Protocol  H8H -MC-LAIJ Rando mized Controlled Trial of Lasmiditan Over Four Migraine 
Attacks (CENTURION)
1. Synopsis , Objectives/Endpoints
Only rows with additions or deletions are included below .
Objectives Endpoints
Secondary
     Efficacy
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg in triptan nonrespo ndersThe proportions of patients in the subpopulation of triptan 
nonresponders that achieve primary and secondary 
objectives in each group during the first attack
The proportions of patients in the subpopulation of triptan 
nonresponders versus other patients thatachieve primary 
and secondary objectives in each group during the first 
attack
1. Synopsis , Statistical A nalysis
Efficacy analyses will be conducted on the intent-to-treat (ITT) efficacy popul ation. This set 
includes all rando mized patients who used at least [ADDRESS_1240998] attack in the lasmiditan 100- mg group with 
placebo.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1240999] 3 evaluable attacks in the 
lasmiditan 200 -mg and 100 -mg groups will be compared to the results of the evaluable attacks 
treated with placebo in the control group s.An attack will be defined as evaluabl e if there is non-
missing informat ion on 2- hour pain freedo m.
2. Schedule of A ctivities   
Only rows with additions or deletions are included below .
H8H-MC-LAIJ(b) Clinical Protocol Page 79
LY573144Table LAIJ.2.1 . Schedule of A ctivities
Visit 1a
ScreeningVisit 2
Baseline 
(at site)Treatment Attack 1 -4b
All attacks:  Mod/sev within 4 hrs of onset
Attack 2:  ≥48 hrs after dosing Attack 1
Attack 3:  ≥48 hrs after dosing Attack 2
Attack 4:  ≥48 hrs after dosing Attack 3Visit 6 EoS 
(at site)
or EDCcNotes
V1+3 -30 
days
(pending 
lab 
results)Visit 3 
Phone Call 
1 after 
Attack 1 or
at 1 mod±1 
wk after V2Visit 4 
Site Visit
at +2 mos±1 
wk after V2 Visit 5 
Phone Call 2 
at 3 mos±1 
wk after V2≥[ADDRESS_1241000] treated 
attack (=last 
dose) OR at 4 
mos±2 wks after 
V2
C-SSRS -BL/screening 
versione X
C-SSRS -since last visit 
versione X X X
   Self-Harm Supplement Form X X X X
   Self-Harm Follow -up Form fX X X X
bAttacks treated do not need to be consecutive.  Minimum amount of time between attacks is 48 hours (determined by [CONTACT_886866], i.e., the next attack 
may not be treated with study drug within 48 hours of taking study drug).  During the treatment period, unscheduled visits ma y be completed at the discretion 
of the investigator.   In the event of abnormal laboratory findings, including but not limited to tests that may indicate abnormal liver function, repeat or 
additional laboratory testing may be required outside a scheduled clinic visit.
eAdapted for the assessment of the ideation and behav ior categories only (the Intensity of Ideation and Lethality of Behavior sections are removed).
fRequired if triggered by [CONTACT_47584] -Harm Supplement Form per instructions.
H8H-MC-LAIJ(b) Clinical Protocol Page 80
LY5731444. Objectives and Endpoints
Only rows with additions or deletion s are included below .
Objectives Endpoints
Secondary
     Efficacy
To evaluate the efficacy of lasmiditan 200 mg 
and 100 mg in triptan nonrespo ndersThe proportions of patients in the subpopulation of triptan 
nonresponders that achieve primary and secondary 
objectives in each group during the first attack
The proportions of patients in the subpopulation of triptan 
nonresponders versus other patients thatachieve primary 
and secondary objectives in each group during the first 
attack
6.2. Exclusion Criteria   
[18] history , within past 12 m onths, of chronic migraine or other forms of primary  or 
secondary  chronic headache disorder (eg ,hemicranias continu a, medicati on overuse 
headache where headache frequency is ≥15 headache days per month [Appendix 5 and 
Appendix 6 ])
9.4.4 Other Tests
Columbia Suicide- Severity Rating Scale (C -SSRS):   A scale that captures the occurrence, 
severit y,and frequency  of suicide -related thoughts and behaviors during the assessment period
(Posner et al. 2011) .  The scale inclu des suggested questions to solicit the ty pe of informat ion 
needed to determine if a suicide -related thought or behavior occurred.  The C -SSRS is 
administered by  [CONTACT_878700] 1 y ear of pat ient 
care/clinical experience according to the Schedule of Act ivities (Secti on2).  Thetool was 
developed by [CONTACT_886855] (NIMH
)trial group (T reatm ent of 
Adolescent Suicide Attempters Study ) for the purpose of being a counterpart to the Columbia 
Classificat ion Algorithm o f Suicide Assessment (C -CASA) categori zation of  suicidal  events . 
Two versions of the C- SSRS will be used:
The screening version will be ad ministered at Screening/Visit 1
The “since last visit” versio n will be administered at Visit 2 and Visit 4 (at 
2months) and at V6 (EoS)
For thisstudy , the C -SSRS i s adapted for the assessment of the ideati on and behavior categories 
only.The Intensit y of Ideati on and Lethalit y of Behavi or secti ons are rem oved.
The nonleading AE collect ion shoul d occur pri or to the collect ion of the C -SSRS. If a 
suicide-related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collect ion, sites shoul d not change the AE form. If an adverse event i s seri ous or 
leads to di scont inuat ion, thi s is an exception where the SAE and/or AE leading to 
H8H-MC-LAIJ(b) Clinical Protocol Page 81
LY573144discontinuat ion shoul d be included on the A E form and the process for reportin g SAEs shoul d be 
followed.
Assessment of driving accidents/violations:   In order to further evaluate the impact of 
lasmiditan on driving, patients will be asked to respond to questions related to motor 
vehicle accidents a nd m oving vio lations an assessment of driving accidents/vio lations 
will be conducted by [CONTACT_886856] (Secti on2).  
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1241001] any postdose efficacy 
assessments .  
ITT consistency All randomized patients who experience a sufficient number of successes or  
failures (defined in Sect ion10.3.1 ) during ITT -evaluable attacks for any of the 
consistency analyses participants from ITT efficacy population with sufficient 
information on consistency of 2-hour headache pain freedom as defined in 
Section 10.3.1.
mITT consistency All randomized patients who experience a sufficient number of successes or  
failures (defined in Section 10.3.1 ) during mITT -evaluable attacks for any of the 
consistency analyses.
Safety All randomized patients who take at least 1 dose of study drug, regardless of 
whether or not they undergo any  study  assessments .  
10.3.1. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y ofLilly o r its desi gnee. The statistical 
analysis plan (SAP) will be finalized and approved prior to unblinding of treatment at database 
lock.
Efficacy analyses will be conducted on the ITTefficacy popul ation.  Thi s set includes all 
rando mized patients who use dat least [ADDRESS_1241002] mild pain severit y with any postdose pain severit y asssessments at 
or before 2 hours postdose and had any postdose efficacy assessments .  Pati ents will be evaluated 
by [CONTACT_886867] .  
Consistency analyses will be conducted on the ITT consistency  popul ation.  This set includes all 
rando mized patients who experienced a sufficient number of successes or failures during ITT -
evaluable attacks for any  of the consistency  analyses.  The “sufficient number” is defined 
differently for the There are 2 endpoints related to consistency ( iethat i s, 2 out of 3 attacks and 3 
out of 4 attacks ).:  
Two of 3:  To evaluate the [ADDRESS_1241003] either 2 successes 
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1241004] 2 or 3 ITT -evaluable attacks , regardless o f whether or not 
they had data for all attacks .  Attacks treated with placebo are used for comparison.
Three of 4:  To evaluate the [ADDRESS_1241005] either 3 successes 
or 2 failures during ITT -evaluable attacks , regardl ess of whether or not they  had data for 
all attacks.  For the control group, the results of all evalua ble attacks treated with 
lasmiditan 50 mg or placebo will be included.  The control group is used for comparison. 
For analyses where mITT populations are specified, the definit ions are the same as for ITT 
popul ations, except based on mITT -evaluable attack s.
…
[IP_ADDRESS] . Primary Analyses
The firstprimary object ive of this study  is to assess the efficacy o f lasmiditan 200 m g and 
lasmiditan 100 mg on migraine headache pain freedom .  The primary measurement is the 
proporti on of  patients having pain free dom (defined as mild, moderate, or severe headache pain
beco ming none) at [ADDRESS_1241006] attack.   This analysis will be performed on 
the ITT efficacy popul ation.
…
Logist ic regressio n with categori cal term s for treatment and either country  or geographic region 
will be used to statist ically evaluate the proportions of patients achieving migraine headache pain 
freedo min first attack for lasmidi tan treatm ent groups versus placebo and also in the consistency 
analyses co mpar ing lasmiditan treatm entgroups versus placebo.  In order to control for overall 
type I error, the primary analyses will be tested using a multiple comparisons procedure that 
preserves overall ty pe I error at [ADDRESS_1241007] any postbaseline efficacy  
data.Addit ionally, the consistency endpo ints will be repeated in the mITT consistency 
popul ation.
[IP_ADDRESS] . Secondary A nalyses
The sec ondary  measures will  be analyzed using the ITT efficacy and ITT consistency 
popul ations.
H8H-MC-LAIJ(b) Clinical Protocol Page [ADDRESS_1241008] 
attack and 2 out of 3 consistency endpo ints.  The comparisons will be between lasmiditan groups 
versus control group for the 3 out of 4 attacks consistency endpo ints.  For continuous endpo ints, 
analysis of variance (ANOVA) or analysis of covariance ( ANCOVA )will be used to assess the 
effect of lasmiditan.  The raw total score or change fro m baseline of total  score are dependent 
variables. The m odel includes fixed categorical effect of treatm ent and geographic region 
country and baseline as covari ate.  The primary comparison will be between the lasmidi tan 
groups versus placebo.
…
[IP_ADDRESS]. Tertiary/Exploratory A nalyses 
…
Analysis of varia nce or ANCOVA will be used to assess the effect of lasmiditan over placebo or 
control  for continuous endpo ints.  The model includes fixed categorical effect of treatment and 
geographi c regi on country and baseline as covariate.
Appendix 1. A bbreviations and Definitions
TEAE Treatment -emergent adverse event:  An AE with time and date of onset on or within [ADDRESS_1241009] a causal relationship with this 
treatment.
Appendix 6. Medication Overu se Headache Diagnostic Criteria
International Classification of Headache Disorders -3 Diagnosis and Diagnostic Criteria per 
International Headache Society 2018Diagnostic criteria:
Leo Document ID = 505af348-4de2-4fed-aa47-a2f8d997e1b7
Approver: 
Approval Date & Time: 30-Mar-2020 15:47:16 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 30-Mar-2020 20:09:21 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]